

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Attention: Application Branch

MAERTENS et al

Atty. Dkt. 2551-48

Serial No. To Be Assd

Filed: October 12, 2000

Date: October 12, 2000

IMPROVED IMMUNODIAGNOSTIC ASSAYS USING REDUCING AGENTS

Assistant Commissioner for Patents

Washington, D.C. 20231

The attached completes filing of the above-identified patent application:

- ☐ Signed Rule 63 Declaration alone OR
- ☒ Signed Declaration plus attached copy of originally filed specification/drawings.
- ☒ **NOTICE TO FILE MISSING PARTS OF APPLICATION FILING DATE GRANTED** form.
- ☐ Record and return the attached assignment.
- ☐ Priority is hereby claimed per Rule 55 & 35 USC119 based on prior foreign application(s) Nos.:

Application Nos.**Country****Filing Date**

98870087.8

Ep

17 April 1998

PCT/EP99/02547

Ep

15 April 1999

PCT/EP99/02547

April 15, 1999

respectively.

- ☐ This application is based on the following prior provisional application(s):

Application No.**Filing Date**

respectively and priority is hereby claimed therefrom.

Certified copy(ies) of foreign and/or provisional application(s): ☐ attached; ☐ already filed on ____.

in U.S. Application Serial No. ____, filed on ____.

- ☒ The undersigned verifies that the above-identified application is identical to: PCT/EP99/02547 filed April 15, 1999, as amended on
- ☐ Verified Statement attached establishing "small entity" status (Rules 9 & 27)
- ☒ Also attached: Preliminary Amendment, IDS, Letter, paper and computer readable copies of Sequence Listing

Fees are attached as calculated below:

Basic filing fee

Total Effective claims	35	- 20 =	15	x \$	18.00	\$	710.00
Independent claims	5	- 3 =	2	x \$	80.00	\$	270.00
						\$	160.00

If any proper multiple dependent claims now added for first time, add \$270.00 (ignore improper)

FILING FEE \$ 1,140.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$390.00/2 months; \$890.00/3 months; \$1390.00/4 months)

Surcharge (\$) if Declaration or filing fee first now submitted \$ 0.00

FIRST SUBTOTAL \$ 1,140.00

If "small entity," enter half (1/2) of subtotal and subtract -\$ 0.00

SECOND SUBTOTAL \$ 1,140.00

Assignment Recording Fee (\$40.00) \$ 0.00

TOTAL FEE TO BE CHARGED TO \$ 1,140.00**DEPOSIT ACCOUNT**

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension. The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:

NIXON & VANDERHYE P.C.

By Atty: B.J. Sadoff, Reg. No. 36,663

Signature: JC913 U.S. PTO
09/686964
10/12/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAERTENS et al

Atty. Ref.: 2551-48

Serial No. To Be Assigned

Group:

Filed: October 12, 2000

Examiner:

For: IMPROVED IMMUNODIAGNOSTIC ASSAYS USING
REDUCING AGENTS

October 12, 2000

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

In order to place the above-identified application in better condition for examination, please
amend the application as follows:

IN THE SPECIFICATION

Amend the Specification as follows:

Insert the attached Sequence Listing after the claims pages.

IN THE CLAIMS

Claim 7, line 1, change, "any of claims 1 to 6" to - -claim 1--.

Claim 8, line 1, change, "any of claims 1 to 7" to - -claim 1--.

Claim 9, line 1, change, "any of claims 2 to 8" to - -claim 2--.

Claim 10, line 1, change, "any of claims 2 to 9" to - -claim 2--.

Claim 11, line 1, change, "any of claims 2 to 9" to - -claim 2--.

Claim 13, line 1, change, "any of claims 2 to 9" to - -claim 2--.

Claim 15, line 1, change, "any of claims 2 to 9" to - -claim 2--.

Claim 17, line 1, change, "Use of an assay according to claims 10 to 16" to - -A method of - - and
line 2, change, "as described in claim 1" to - -comprising detecting said antibodies in a method of claim 2

--.

Claim 23, line 1, delete, "or 22".

Claim 25, line 1, delete, "or 22".

Claim 26, line 1, delete, "or 22" and line 2, delete, "according to claim 21 or 22".

Claim 27, line 1, delete, "or 22" and line 2, delete, "according to claim 26".

Claim 28, line 2, delete, "or 22".

Claim 30, line 1, delete, "or 29".

Claim 31, line 1, delete, "or 29".

Claim 32, line 1, delete, "or 29".

Claim 33, line 1, delete, "or 29".

Claim 35, line 1, delete, "or 29".

REMARKS

The above amendments are made to place the claims in a more traditional format. The specification has been amended to include a Sequence Listing. The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B.J. Sadoff
Reg. No. 36,663

BJS:pd
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

IMPROVED IMMUNODIAGNOSTIC ASSAYS USING REDUCING AGENTS

FIELD OF THE INVENTION

The present invention relates to the field of diagnosis and treatment of HCV infection. More particularly, the present invention relates to HCV NS3 helicase and its uses. Also the present invention relates to improved immunodiagnostic assays

BACKGROUND OF THE INVENTION

Hepatitis C Viruses (HCV) constitute a genus within the Flaviviridae, with closest homology to the hepatitis G and GB viruses, and Pestiviruses. The positive-stranded RNA genome encodes at least 9 proteins. Core, E1, and E2 constitute the structural proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B are non-structural (NS) proteins. HCV isolates display high levels of sequence heterogeneity allowing classification into at least 11 types and 90 subtypes (Maertens and Stuyver, 1997). HCV infection of the human liver is often clinically benign, with mild icterus in the acute phase. The disease may even go unnoticed in some cases of acute resolving hepatitis C. In the majority (>70%) of cases, however, HCV infection leads to chronic persistent or active infection, often with complications of liver cirrhosis and auto-immune disorders. Hepatocellular carcinoma may occur after about 20 to 35 years (Saito et al , 1990), sometimes even without the intermediate phase of cirrhosis. No prophylaxis is available today and treatment with interferon-alpha (IFN- α) only leads to long-term resolution in about 4 to 36% of treated cases, depending on the HCV genotype (Maertens and Stuyver, 1997)

Since productive culture methods for HCV are currently not available, and since only minute amounts of HCV antigens circulate in the infected patient, direct detection of HCV particles cannot be performed routinely, and indirect diagnosis is only possible using cumbersome amplification techniques for HCV RNA detection. Unlike with many other viral infections, HCV particles generally persist in the blood, liver, and lymphocytes despite the presence of cellular and humoral immune response to most of the HCV proteins. HCV antibodies can be conveniently

detected by Elisa techniques which allow high throughput screening in blood banks and clinical laboratories. Supplementary antibody testing is required and is now mandatory in most countries. True HCV reactivity is thus discriminated from false reactivity, which may be caused by non-specific binding of serum or plasma immunoglobulines or anti-idiotypic components to the coating or blocking reagents, or to contaminants present in HCV antigen preparations, or even to fusion parts or non-specific regions of the recombinant antigens themselves (McFarlane et al., 1990). HCV RNA detection by PCR or branched DNA (bDNA) techniques have recently been introduced to monitor chronic HCV disease, especially during therapy. Surprisingly, HCV RNA detection is sometimes employed to confirm HCV Ab screening tests, despite the fact that only ~70-94% of repeatedly HCV Ab positive patient samples are positive by nested PCR (Marin et al., 1994). Of HCV Ab positive blood donors, who usually present with milder forms of the disease and low HCV RNA levels, confirmation by nested PCR is usually in the order of ~40% (Waumans et al., 1993, Stuyver et al., 1996). Strip-based assays therefore provide the only reliable alternative for HCV Ab confirmation. Even in the case of an indeterminate result in the confirmatory assay, serological follow up of the patient rather than HCV RNA detection is advisable (Di Bisceglie et al., 1998). Since native HCV antigens are not available in sufficient quantities, such confirmatory assays incorporate synthetic peptides and/or recombinant fragments of HCV proteins. One of the most critical issues in the confirmation of antibodies constitutes the reactivity of the NS3 protein (Zaaijer et al., 1994). NS3 antibodies often appear first in seroconversion series and the reactivity of the NS3 protein seems to be different in the different commercial assays available today.

Innogenetics introduced the concept of strip technology in which usually a combination of synthetic peptides and recombinant proteins are applied as discrete lines in an ordered and easily readable fashion. The INNO-LIA HIV Ab tests have proven to be superior to routinely used western blots (Poller et al., 1990). The Line Immuno Assay allows multiparameter testing and thus enables incorporation of cutoff and other rating systems, sample addition control, as well as testing for false reactivity to non-HCV proteins used as carrier or fusion partner required for some antigens in the Elisa test. In principle, the test format allows to combine antigens of different aetiological agents or phenotypically linked conditions into a single test.

The INNO-LIA HCV Ab III is a 3rd generation Line Immuno Assay which incorporates HCV antigens derived from the Core region, the E2 hypervariable region (HVR), the NS3

helicase region, and the NS4A, NS4B, and NS5A regions. In the third generation assay, highly purified recombinant subtype 1b NS3 protein and E2 peptides enabled superior sensitivity while safeguarding the reliable specificity which is characteristic of peptide-based tests (Peeters et al., 1993). Perhaps one of the most important features of this assay is its unprecedented correlation with HCV RNA positivity (Claeys et al., 1992; De Beenhouwer et al., 1992).

5 The antigens are coated as 6 discrete lines on a nylon strip with plastic backing. In addition, four control lines are coated on each strip: anti-streptavidin, 3+ positive control (anti-human Ig), 1+ positive control (human IgG), and the = cutoff line (human IgG). A diluted test sample is incubated in a trough together with the LIA III strip. If present in the sample, HCV antibodies will bind to the HCV antigen lines on the strip. Subsequently, an affinity-purified alkaline phosphatase labelled goat anti-human IgG (H+L) conjugate is added and reacts with specific HCV antigen/antibody complexes if previously formed. Incubation with enzyme substrate produces a chestnut-like color, the intensity of which is proportionate to the amount of HCV-specific antibody captured from the sample on any given line. Color development is stopped with sulphuric acid. If no HCV-specific antibodies are present, the conjugate only binds to the ±, 1+, and 3+ control lines. If the addition of sample is omitted, only the ± and 1+ control lines will be stained.

DEFINITIONS

The following definitions serve to illustrate the different terms and expressions used in the present invention.

20 The term 'HCV NS3' protein' refers to a polypeptide or an analogue thereof (e.g. mimotopes) comprising an amino acid sequence (and/or amino acid analogues) defining at least one HCV epitope of either HCV NS3 protease or helicase.

 The term 'hepatitis C virus envelope protein' refers to a polypeptide or an analogue thereof (e.g. mimotopes) comprising an amino acid sequence (and/or amino acid analogues) defining at least one HCV epitope of either the E1 or the E2 region (see WO 96/04385 of which the contents are hereby incorporated by reference).

25 It should also be understood that the isolates (biological samples) used in the examples

section of the present invention were not intended to limit the scope of the invention and that any HCV isolate belonging to type 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or any other new genotype of HCV is a suitable source of HCV sequence for the practice of the present invention.

5 The HCV antigens used in the present invention may be full-length viral proteins, substantially full-length versions thereof, or functional fragments thereof (e.g. fragments which are not missing sequence essential to the formation or retention of an epitope). Furthermore, the HCV antigens of the present invention can also include other sequences that do not block or prevent the formation of any conformational epitope of interest. The presence or absence of a conformational epitope can be readily determined through screening the antigen of interest with an antibody (polyclonal serum or monoclonal antibody) and comparing its reactivity to that of a denatured version of the antigen which retains only linear epitopes (if any). When in such screening polyclonal antibodies are used, it may be advantageous to adsorb the polyclonal serum first with the denatured antigen and see if it retains antibodies to the antigen of interest.

10 The term 'fusion polypeptide' intends a polypeptide in which the antigen(s), in particularly HCV antigen(s), are part of a single continuous chain of amino acids, which chain does not occur in nature. The HCV antigens may be connected directly to each other by peptide bonds or be separated by spacer amino acid sequences. The fusion polypeptides may also contain amino acid sequences exogenous to HCV.

15 The term 'solid phase' or 'solid support' means a solid body to which the individual HCV antigens or the fusion polypeptide comprised of HCV antigens are bound covalently or by noncovalent means such as by hydrophobic adsorption. Examples of solid phases are microtiter plates, membrane strips such as nylon or nitrocellulose strips, and silicon chips.

20 The term 'biological sample' intends a fluid or tissue of a mammalian individual (e.g. an anthropoid, a human) that commonly contains antibodies produced by the individual, more particularly antibodies against HCV. The fluid or tissue may also contain HCV antigen. Such components are known in the art and include, without limitation, blood, plasma, serum, urine, spinal fluid, lymph fluid, secretions of the respiratory, intestinal or genitourinary tracts, tears, saliva, milk, white blood cells and myelomas. Body components include biological liquids. The term 'biological liquid' refers to a fluid obtained from an organism. Some biological fluids
25 are used as a source of other products, such as clotting factors (e.g. Factor VIII), serum
30

albumin, growth hormone and the like. In such cases, it is important that the source of biological fluid be free of contamination by virus such as HCV.

The term 'immunologically reactive' means that the antigen in question will react specifically with anti-HCV antibodies present in a body component from an HCV infected individual or an immunized individual.

5 The term 'immune complex' intends the combination formed when an antibody binds to an epitope on an antigen.

The terms E1 and E2 as used herein are fully described in WO 96/04385 of which the content is incorporated by reference in the present description

0566964-10:1200
15 The term 'purified' as applied to proteins herein refers to a composition wherein the desired protein comprises at least 35% of the total protein component in the composition. The desired protein preferably comprises at least 40%, more preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, even more preferably at least about 80%, even more preferably at least about 85%, even more preferably at least about 90%, and most preferably at least about 95% of the total protein component. The composition may contain other compounds such as carbohydrates, salts, lipids, solvents, and the like, without affecting the determination of the percentage purity as used herein. An 'isolated' HCV protein intends an HCV protein composition that is at least 35% pure.

20 The term 'essentially purified proteins' refers to proteins purified such that they can be used for in vitro diagnostic methods and as a therapeutic compound. These proteins are substantially free from cellular proteins or DNA, vector-derived proteins or DNA, or other HCV viral components. Usually these proteins are purified to homogeneity (at least 80% pure, preferably, 85%, more preferably, 90%, more preferably 95%, more preferably 97%, more preferably 98%, more preferably 99%, even more preferably 99.5%, and most preferably the contaminating proteins should be undetectable by conventional methods like SDS-PAGE and
25 silver staining.

The term 'recombinantly expressed' used within the context of the present invention refers to the fact that the proteins of the present invention are produced by recombinant expression methods be it in prokaryotes, or lower or higher eukaryotes as discussed in detail below.

30 The term 'lower eukaryote' refers to host cells such as yeast, fungi and the like. Lower

eukaryotes are generally (but not necessarily) unicellular. Preferred lower eukaryotes are yeasts, particularly species within *Saccharomyces*, *Schizosaccharomyces*, *Kluyveromyces*, *Pichia* (e.g. *Pichia pastoris*), *Hansenula* (e.g. *Hansenula polymorpha*), *Yarrowia*, *Schwanniomyces*, *Zygosaccharomyces* and the like. *Saccharomyces cerevisiae*, *S. carlsbergensis* and *K. lactis* are the most commonly used yeast hosts

5 The term 'prokaryotes' refers to hosts such as *E.coli*, *Lactobacillus*, *Lactococcus*, *Salmonella*, *Streptococcus*, *Bacillus subtilis* or *Streptomyces*. Also these hosts are contemplated within the present invention.

10 The term 'higher eukaryote' refers to host cells derived from higher animals, such as mammals, reptiles, insects, and the like. Presently preferred higher eukaryote host cells are derived from Chinese hamster (e.g. CHO), monkey (e.g. COS and Vero cells), baby hamster kidney (BHK), pig kidney (PK15), rabbit kidney 13 cells (RK13), the human osteosarcoma cell line 143 B, the human cell line HeLa and human hepatoma cell lines like Hep G2, and insect cell lines (e.g. *Spodoptera frugiperda*). The host cells may be provided in suspension or flask cultures, tissue cultures, organ cultures and the like. Alternatively the host cells may also be transgenic animals.

15 The term 'polypeptide' refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogues of an amino acid (including, for example, unnatural amino acids, PNA, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

20 The term 'recombinant polynucleotide or nucleic acid' intends a polynucleotide or nucleic acid of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature.

25 The term 'recombinant host cells', 'host cells', 'cells', 'cell lines', 'cell cultures', and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as

30

unicellular entities refer to cells which can be or have been. used as recipients for a recombinant vector or other transfer polynucleotide. and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent. due to natural. accidental. or deliberate mutation.

5 The term 'replicon' is any genetic element. e.g., a plasmid, a chromosome, a virus, a cosmid, etc., that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control.

The term 'vector' is a replicon further comprising sequences providing replication and/or expression of a desired open reading frame.

10 The term 'control sequence' refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism: in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and terminators; in eukaryotes, generally, such control sequences include promoters. and may include enhancers. The term 'control sequences' is intended to include, at a minimum. all components whose presence is necessary for expression. and may also include additional components whose presence is advantageous, for example, leader sequences which govern secretion.

15 The term 'promoter' is a nucleotide sequence which is comprised of consensus sequences which allow the binding of RNA polymerase to the DNA template in a manner such that mRNA production initiates at the normal transcription initiation site for the adjacent structural gene.

20 The expression 'operably linked' refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence 'operably linked' to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

25 An 'open reading frame' (ORF) is a region of a polynucleotide sequence which encodes a polypeptide and does not contain stop codons in the reading frame selected; this region may represent a portion of a coding sequence or a total coding sequence.

30 A 'coding sequence' is a polynucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory

sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include but is not limited to mRNA, viral RNA, DNA (including cDNA), and recombinant polynucleotide sequences.

As used herein, 'epitope' or 'antigenic determinant' means an amino acid sequence that is immunoreactive. Generally an epitope consists of at least 3 to 4 amino acids, and more usually, consists of at least 5 or 6 amino acids, sometimes the epitope consists of about 7 to 8, or even about 10 amino acids. As used herein, an epitope of a designated polypeptide denotes epitopes with the same amino acid sequence as the epitope in the designated polypeptide, and immunologic equivalents thereof. Such equivalents also include strain, subtype (=genotype), or type(group)-specific variants, e.g. of the currently known sequences or strains belonging to genotypes 1a, 1b, 1c, 1d, 1e, 1f, 2a, 2b, 2c, 2d, 2e, 2f, 2g, 2h, 2i, 3a, 3b, 3c, 3d, 3e, 3f, 3g, 4a, 4b, 4c, 4d, 4e, 4f, 4g, 4h, 4i, 4j, 4k, 4l, 5a, 5b, 6a, 6b, 6c, 7a, 7b, 7c, 8a, 8b, 9a, 9b, 10a, 11a, 12a or any other newly defined HCV (sub)type. It is to be understood that the amino acids constituting the epitope need not be part of a linear sequence, but may be interspersed by one or more series of any number of amino acids, thus forming a conformational epitope.

The term 'immunogenic' refers to the ability of a substance to cause a humoral and/or cellular response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant. 'Neutralization' refers to an immune response that blocks the infectivity, either partially or fully, of an infectious agent. A 'vaccine' is an immunogenic composition capable of eliciting protection against HCV, whether partial or complete. A vaccine may also be useful for treatment of an individual, in which case it is called a therapeutic vaccine.

The term 'therapeutic' refers to a composition capable of treating HCV infection.

The term 'effective amount' refers to an amount of epitope-bearing polypeptide sufficient to induce an immunogenic response in the individual to which it is administered, or to otherwise detectably immunoreact in its intended system (e.g., immunoassay). Preferably, the effective amount is sufficient to effect treatment, as defined above. The exact amount necessary will vary according to the application.

The term 'antibody' refers to polyclonal or monoclonal antibodies. The term 'monoclonal antibody' refers to an antibody composition having a homogeneous antibody population. The term

is not limited regarding the species or source of the antibody, nor is it intended to be limited by the manner in which it is made. It should be noted that also humanized antibodies, single chain antibody or any other fragment thereof which has largely retained the specificity of said antibody are covered by the present invention

As used herein, the term 'humanized antibody' means that at least a portion of the framework regions of an immunoglobulin are derived from human immunoglobulin sequences

As used herein, the term 'single chain antibody' refers to antibodies prepared by determining the binding domains (both heavy and light chains) of a binding antibody, and supplying a linking moiety which permits preservation of the binding function.

As used herein, the term 'fragments (of antibodies)' refers to F_{ab} , $F_{(ab)_2}$, F_v , and other fragments which retain the antigen binding function and specificity of the parent antibody

AIMS OF THE INVENTION

It is an aim of the present invention to provide improved HCV diagnostic assay components and therapeutic proteins.

More particularly it is an aim of the present invention to provide improved HCV NS3 protein preparations for use in HCV antibody diagnosis and/or HCV treatment.

It is further an aim of the present invention to provide a method for increasing the reactivity of HCV antibodies with recombinant or synthetic NS3 helicase protein or part thereof present on a solid phase.

It is also an aim of the present invention to provide a novel method for purifying cysteine containing recombinant proteins, more particularly recombinant HCV proteins.

It is also an aim of the present invention to provide new HCV NS3 protein encoding sequences.

It is also an aim of the present invention to provide new HCV NS3 protein encoding sequences of which the product does not react with falsely positive HCV samples.

It is also an aim of the present invention to provide a method for detecting the nucleic acids of the invention.

It is also an aim of the present invention to provide probes and primers for the detection

of the nucleic acids of the invention.

It is also an aim of the present invention to provide a diagnostic kit for the detection of the nucleic acids of the invention.

It is another aim of the present invention to provide new HCV NS3 polypeptides.

It is another aim of the present invention to provide new HCV NS3 polypeptides which do not react with falsely positive HCV samples.

It is another aim of the present invention to provide a pharmaceutical composition to prevent or treat HCV infection.

It is another aim of the present invention to provide a method for the detection of the polypeptides of the invention.

It is another aim of the present invention to provide antibodies to the polypeptides of the present invention for use in passive immunization and/or therapy.

It is another aim of the present invention to provide a method for the production of the polypeptides of the invention.

All the aims of the present invention are considered to have been met by the embodiments as set out below.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates more particularly to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent. As is demonstrated in the Examples section the present inventors have found that the presence of a reducing agent such as DTT, besides an antigen coated to a solid phase, renders a solid phase immunassay coupled antigen much more reactive with antibodies directed to said antigen. Also in solution, the antigen is rendered more reactive by reduction.

A reducing agent according to the present invention is any agent which achieves reduction of S-S disulfide bridges. Reduction of the 'S-S' disulfide bridges is a chemical reaction whereby the disulfides are reduced to thiol (-SH). The disulfide bridge breaking agents and methods disclosed in WO 96/04385 are hereby incorporated by reference in the present description. 'S-S' Reduction can be obtained by (1) enzymatic cascade pathways or by

(2) reducing compounds. Enzymes like thioredoxin, glutaredoxin are known to be involved in the in vivo reduction of disulfides and have also been shown to be effective in reducing 'S-S' bridges in vitro. Disulfide bonds are rapidly cleaved by reduced thioredoxin at pH 7.0, with an apparent second order rate that is around 10^4 times larger than the corresponding rate constant for the reaction with DTT. The reduction kinetic can be dramatically increased by preincubation the protein solution with 1 mM DTT or dihydrolipoamide (Holmgren, 1979).

Thiol compounds able to reduce protein disulfide bridges are for instance Dithiothreitol (DTT), Dithioerythritol (DTE), β -mercaptoethanol, thiocarbamates, bis(2-mercaptoethyl) sulfone and N,N'-bis(mercaptoacetyl)hydrazine, and sodium-dithionite.

Reducing agents without thiol groups like ascorbate or stannous chloride (SnCl_2), which have been shown to be very useful in the reduction of disulfide bridges in monoclonal antibodies (Thakur et al., 1991), may also be used for the reduction of NS3. Sodium borohydride treatment has been shown to be effective for the reduction of disulfide bridges in peptides (Gailit, 1993). Tris (2-carboxyethyl)phosphine (TCEP) is able to reduce disulfides at low pH (Burns et al., 1991). Selenol catalyses the reduction of disulfide to thiols when DTT or sodium borohydride is used as reductant. Selenocysteamine, a commercially available diselenide, was used as precursor of the catalyst (Singh and Kats, 1995).

The present invention relates more particularly to a method for producing an immunoassay as defined above wherein said reducing agent is added to said solid phase during the steps of coating, blocking and/or fixation of said antigen to said solid phase.

The present invention also relates to a method for carrying out an immunoassay as defined above wherein said reducing agent is added during the step of pretreatment of the solid phase.

Coating conditions can vary widely as known by the skilled person and involves applying to a solid phase the protein and allowing a reaction to occur resulting in the binding of the protein to the solid phase. Binding can be, but is not restricted to, covalently hydrophobic or ionic bonds, Van Der Waels forces or hydrogen bridges. Different buffers known by the skilled man may be used for this step, including but not limited to carbamate and phosphate buffers.

Blocking can occur via any method known in the art and can for instance also be performed using albumin, serum proteins, polyvinylpyrrolidone (PVP), detergents, gelatines,

polyvinylalcohol (PVA) or caseine.

Fixation can occur according to any method known in the art.

Further examples of blocking, fixation and coating conditions are given in the Examples section.

The present invention relates even more particularly to a method as defined above wherein said reducing agent is added to said solid phase during the step of coating of the antigen to the solid phase. Examples of coating buffers are given in the Examples section. All other known coating buffers known in the art also form part of the present disclosure.

The present invention relates also to a method as defined above, wherein said reducing agent is added to said solid phase during the step of blocking said solid phase, comprising the antigen which had been applied thereto in the presence or absence of a reducing agent. Examples of blocking buffers are given in the Examples section. All other known blocking buffers known in the art also form part of the present disclosure.

The present invention relates also to a method as defined above, wherein said reducing agent is added to said solid phase during the step of fixation of the coated antigen to said solid phase comprising the antigen which had been applied thereto in the presence or absence of a reducing agent. The fixation step may also have been preceded by a blocking step in the presence or absence of a reducing agent. Examples of fixation buffers are given in the Examples section. All other known fixation buffers known in the art also form part of the present disclosure.

The present invention also relates to a method for carrying out an immunoassay as defined above wherein said reducing agent is added during the step of pretreatment of the solid phase before addition of the sample. Pretreatment of the plates can be done with plates that have been treated with a reducing agent in the coating, blocking and/or fixation step or with plates that have not been previously treated with a reducing agent.

Finally, the reducing agent may also be added during any further steps carried out in enzyme immunoassays, as part of the present invention, possibly after application of a reducing agent in one or more of the above 4 steps of coating, blocking, fixation and/or pretreatment. Such further steps include but are not limited to incubation the antibodies, detecting bound antibodies and color development.

The present invention relates preferably to a method as defined above wherein said

reducing agent is DTT, DTE or TCEP.

The present invention relates also to a method as defined above wherein said reducing agent is used in a concentration range of 0.1 mM to 1 M, more particularly from 0.5 mM to 500 mM, even more particularly from 1 mM to 250 mM, most particularly from 1 to 50 mM. Some applications may require ranges from 0.5 to 50 mM, 1 to 30 mM, 2 to 20 mM, 5 to 15 mM, or about 10 mM reducing agent. Other applications require DTT concentrations of 50-500 mM, 100-300 mM or 200 mM. DTT is particularly preferred as a reducing agent.

The present invention also relates to a method as defined above wherein said antigen is an HCV NS3 protein. More particularly an HCV NS3 helicase. Also preferred is an HCV envelope protein such as E1 and/or E2 protein. Also any other protein known in the art may react better with antibodies against said protein when the protein is added to the solid phase in the presence of DTT, or treated with DTT thereafter.

The present invention also relates to a method as described above wherein said solid phase immunoassay comprises a combination of antigens of different aetiological agents or phenotypically linked conditions.

The present invention also relates to a solid phase immunoassay produced by a method as defined above. More particularly, a kit containing at least a solid phase such as a microtiterplate, a membrane strip or silicon chip which contains an antigen in the presence of a reducing agent.

More particularly, the present invention relates to an ELISA produced by a method as defined above.

In a preferred embodiment, the present invention relates to an ELISA produced by a method as defined above wherein said reducing agent is preferably added in the coating and/or fixation steps. In one preferred embodiment, the reducing agent can be applied in the coating step. In another preferred embodiment, the reducing agent can be applied in the fixation step. In a particularly preferred embodiment the reducing agent is added in both the coating and the fixation step.

In another preferred embodiment, the present invention relates to an ELISA produced by a method as defined above wherein said reducing agent is added during pretreatment of the plates before addition of the sample. Pretreatment of the plates can be done with plates that have been treated with a reducing agent in the coating and/or fixation step or with plates that

have not been previously treated with a reducing agent. The reducing agent may also be added during any further steps carried out in enzyme immunoassays. Such further steps include but are not limited to incubation the antibodies, detecting bound antibodies and color development.

The present invention also relates to an Line Immunoassay (LIA) produced by a method as defined above.

5 In a preferred embodiment, the present invention relates to a Line Immunoassay (LIA) produced by a method as defined above wherein said reducing agent is preferably added in the blocking step and/or washing step. The reducing agent may also be added during any further steps in producing or carrying out the enzyme immunoassays. Such further steps include but are not limited to fixation, pretreatment, incubation the antibodies, detecting bound antibodies and color development.

The present invention also relates to a QUICK assay produced by a method as defined above.


10 In a preferred embodiment, the present invention relates to a QUICK assay produced by a method as defined above wherein said reducing agent is preferably added during the coating of the antigen onto the strip. The QUICK assay is a lateral flow assay in which the antigens are coated onto the strips by spraying. In this assay, the reducing agent is preferably added to the spray solution. The reducing agent may also be added during any further steps in producing or carrying out the enzyme immunoassays. Such further steps include but are not limited to blocking, fixation, pretreatment, incubation the antibodies, detecting bound antibodies and color development.

15 The present invention also relates to the use of an assay as defined above for in vitro diagnosis of antibodies raised against an antigen as defined above.

The present invention also relates to an HCV NS3 protein treated by a method comprising the steps of sulphonation and subsequent desulphonation.



20 Sulphonation and desulphonation is a reaction whereby $-SO_3$ groups are introduced or removed respectively from the protein.

Sulphonation is defined as a process where thiol groups (SH) on proteins (R) and disulphide bonds are converted to S-Sulphonates, according to the following reactions:



The products of the reactions are S-Sulphoproteins which are usually stable at neutral pH. Reaction (1) can be obtained by incubation the protein solution with tetrathionate at pH > 7 (Inglis and Liu, 1970). Reaction (2) proceeds to completion in the presence of copper ions (Cole, 1967). Chan (1968) has shown that treatment of protein with sodium sulfite and catalytic amounts of cysteine in the presence of oxygen gives sulpho-proteins.

Desulfonation can be obtained (1) by an excess of competitive -SH (thiol) groups, (2) by reducing agents or (3) by incubation in non-neutral pH conditions.



Competitive thiol groups may be obtained from low molecular weight compounds or from proteinaceous -SH groups.

Examples of mono- or dithiol containing compounds are: cysteine, cysteamine, reduced glutathion, N-acetyl cysteine, homocysteine, β -mercaptoethanol, thiocarbamates, bis(2-mercaptoethyl)sulphone (BMS) and N,N'-bis(mercaptoacetyl)hydrazine (BMH), 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB or Elman's reagent), Dithiotreitol (DTT) and Dithioerythrithiol (DTE).

The present invention further relates to an HCV NS3 protein as defined above which is additionally treated with a zwitterionic detergent. Empigen is known as betaine and is a particularly preferred example of a zwitterionic detergent. Other suitable detergents are known by the skilled man and are reviewed also in WO 96/04385.

The present invention further relates to a method for purifying a cysteine containing, recombinantly expressed protein, comprising at least 2, preferably 3 or 4, and even more preferably, all of the following steps:

- (a) sulphonation of a lysate from recombinant host cells or lysis of recombinant host cells in the presence of guanidinium chloride (preferably 6 M Gu.HCl) and sulphonation of the cell lysate.
- (b) treatment with a zwitterionic detergent, preferably after removal of the cell debris,
- (c) purification of the sulphonated recombinant protein, or purification of the sulphonated recombinant protein with subsequent removal of the zwitterionic detergent, with said purification being preferably chromatography, more preferably a Ni-IMAC chromatography with said recombinant protein being a His-tagged recombinant protein,
- (d) desulphonation of the sulphonated recombinant protein, preferably with a molar excess of

a reducing agent such as DTT,

(e) storage in the presence of a molar excess of DTT.

Empigen is a particularly preferred example of a zwitterionic detergent. Inclusion of such a zwitterionic detergent and DTT was found to improve the purification protocol for HCV NS3 helicase and HCV envelope proteins.

5 The present invention also relates to an HCV polynucleic acid encoding an HCV NS3 polyprotein as shown in Figure 1 (SEQ ID NOs 3-18) or a unique part of an HCV polynucleic acid having a sequence as represented in Figures 2-1, 3-1, 4-1, 5-1, 6-1, 7-1, and 8-1 (SEQ ID NOs 19, 21, 23, 25, 27, 29 and 31).

The present invention also relates to an HCV polynucleic acid as defined above characterized in Figures 2-1, 3-1, 4-1, 5-1, 6-1, 7-1, and 8-1 and by the fact that its product does not react with false positive HCV samples, or a part thereof which encodes NS3 epitopes which do not react with false positive HCV samples. It was particularly surprising that the proteins coded by the clones represented by SEQ ID NOs 19, 21, 23, 25, 27, 29 and 31 have the property of not reacting with false positive HCV samples, yet they were able to react with most of the known NS3 antibody-positive samples after DTT treatment.

The present invention further relates to a recombinant vector comprising a polynucleic acid as described.

The present invention further relates to a host cell comprising a vector of the invention.

20 The present invention further relates to a method for detecting a nucleic acid of the invention. This detection method can be any method known in the art such as described in detail in WO 96/13590 to Maertens & Stuyver.

More particularly, the present invention relates to a method for detecting a nucleic acid of the invention comprising:

- contacting said nucleic acid with a probe;
- 25 - determining the complex formed between said nucleic acid and said probe.

In accordance, the present invention relates to an isolated nucleic acid as described above or a fragment thereof for use as a probe or a primer.

The present invention further relates to a diagnostic kit for the detection of a nucleic acid sequence as described above, comprising at least one primer and/or at least one probe according to the invention. For a detailed description to an overview of these applications 30 reference is made to WO 96/13590.

In addition to the reactivity gained by reduction, the NS3 reactivity is also severely determined by the sequence of the NS3 antigen.

The present invention therefore also relates to an HCV polypeptide having part or all of the amino acid sequences as shown in Figures 1, 2-2, 3-2, 4-2, 5-2, 6-2, 7-2 and 8-2 (SEQ ID NOs 20, 22, 24, 26, 28, 30, 32). The present invention also relates to an HCV NS3 helicase protein as depicted in Figure 1 (SEQ ID NOs 1-18) or an unique part thereof.

The present invention also relates to an HCV NS3 helicase protein or part thereof containing either S1200, A1218, A1384, P1407, V1412, P1424, or F1444, or a combination of these amino acids with any of the following amino acids L1201, S1222, I1274, S1289, T1321, A1323, T1369, L1382, V1408, A1409, or F1410. Said numbering is according to the commonly accepted HCV amino acid numbering system.

The present invention further relates to a pharmaceutical composition comprising a polypeptide of the invention or any functionally equivalent variant or fragment thereof. The terms "a pharmaceutical composition" relates to a composition or medicament (both terms can be used interchangeably) comprising a polypeptide of the present invention and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably). This pharmaceutical composition can be used as a medicament. This pharmaceutical composition can be used as a medicament for the treatment or prevention of HCV infection. Suitable carriers or excipients known to the skilled man are saline, Ringer's solution, dextrose solution, Hank's solution, fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance isotonicity and chemical stability, buffers and preservatives. Other suitable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids and amino acid copolymers. The "pharmaceutical composition" or "medicament" may be administered by any suitable method within the knowledge of the skilled man. The preferred route of administration is parenterally or a vaccine. In parental or vaccine administration, the medicament of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with the pharmaceutically acceptable excipients as defined above. For vaccine applications or for the generation of polyclonal antiserum/antibodies, for example, the effective amount may vary depending on the species, age, and general condition of the individual, the severity of the condition being treated, the particular polypeptide selected and its mode of administration, etc. It is also believed that effective amounts will be found within

a relatively large, non-critical range. An appropriate effective amount can be readily determined using only routine experimentation. Preferred ranges of NS3 and/or E1 and/or E2 and/or E1/E2 single or specific oligomeric envelope proteins for prophylaxis of HCV disease are 0.01 to 1000 $\mu\text{g}/\text{dose}$, preferably 0.1 to 100 $\mu\text{g}/\text{dose}$, more preferably 1 to 50 $\mu\text{g}/\text{dose}$. Several doses may be needed per individual in order to achieve a sufficient immune response and subsequent protection against HCV disease. In the case of a therapeutic vaccine, the number of required doses may amount to more than 10. Continuous infusion may also be used. If so, the medicament may be infused at a dose between 5 and 20 $\mu\text{g}/\text{kg}/\text{minute}$, more preferably between 7 and 15 $\mu\text{g}/\text{kg}/\text{minute}$. It should also be clear that the pharmaceutical composition of the present invention may comprise a functionally equivalent variant or fragment of the sequences given by SEQ ID NOs 3-18, 20, 22, 24, 26, 28, 30, 32. The latter terms refer to a molecule which contains the full protein sequence of the polypeptide of the invention or part of the protein sequence of the polypeptide of the invention, to which certain modifications have been applied, and which retains all or part of the biological properties of the polypeptide of the invention. Such modifications include but are not limited to the addition of polysaccharide chains, the addition of certain chemical groups, the addition of lipid moieties, the fusion with other peptide or protein sequences and the formation of intramolecular cross-links.

The present invention also relates to an immunoassay comprising an HCV polypeptide as defined above. Said immunoassay can be of any type of format known in the art (see for instance WO 96/13590 and Coligan et al. 1992). In particular, the present invention relates to a method for detecting a polypeptide of the invention comprising:

- contacting said polypeptide with a ligand binding to said polypeptide: —
- determining the complex formed between said polypeptide and said ligand.

In accordance the present invention also relates to a ligand binding to a polypeptide according of the invention. The term "a ligand" refers to any molecule able to bind the polypeptides of the present invention. The latter term specifically refers to polyclonal and/or monoclonal antibodies specifically raised (by any method known in the art) against the polypeptides of the present invention and also encompasses any antibody-like, and other, constructs as described in detail in EP 97870092 0 to Lorré et al. Such antibodies may be very useful for the detection of antigen in biological fluids. Detection of antigen can be done by any immunoassay known in the art such as assays which utilize biotin and avidin or streptavidin, ELISA's and immunoprecipitation, immunohistochemical techniques and agglutination assays.

A detailed description of these assays is given in WO 96/13590 which is hereby incorporated by reference.

Furthermore, said antibodies may be very useful for therapy of HCV or other diseases and may therefore be humanized if generated in a non-human host. In accordance, the present invention relates to compositions of these antibodies in a pharmaceutical acceptable excipient, for use as a medicament.

The present invention also relates to any method for producing and using said polyproteins of the invention. Methods for producing and using HCV polyproteins are disclosed in WO 96/13590. Said uses include not only diagnostic uses but also therapeutic and prophylactic uses. The NS3 proteins of the invention are also particularly suited to be incorporated in vaccine compositions. Said vaccine composition may contain, besides the active ingredient, any type of adjuvant known in the art. The contents of WO 96/13590 are hereby incorporated by reference in the present description. The NS3 proteins of the present invention may also be used in any application where it is applicable to use an NS3 helicase, such as for drug screening purposes.

002101-4969910

=

FIGURE LEGENDS

Figure 1. Amino acid sequence of HCV NS3 clones isolated from HCV subtype 1a and 1b infected sera.

Figure 2-1. DNA coding sequence of the mTNFH6NS3 clone 19b fusion protein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker.

Figure 2-2. Amino Acid sequence of the mTNFH6NS3 clone 19b fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence contains the mTNF fusionpartner, the hexahistidine tag and part of the multilinker.

Figure 3-1. DNA coding sequence of the mTNFH6NS3 clone B9 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker.

Figure 3-2. Amino Acid sequence of the mTNFH6NS3 clone B9 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker.

Figure 4-1. DNA coding sequence of the mTNFH6NS3 Type 3a clone 21 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker.

Figure 4-2. Amino Acid sequence of the mTNFH6NS3 Type 3a clone 21 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker.

Figure 5-1. DNA coding sequence of the mTNFH6NS3 Type 3a clone 32 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker.

Figure 5-2. Amino Acid sequence of the mTNFH6NS3 Type 3a clone 32 fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker

Figure 6-1. DNA coding sequence of the mTNFH6NS3 Type 2a fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker

Figure 6-2. Amino Acid sequence of the mTNFH6NS3 Type 2a fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker

Figure 7-1. DNA coding sequence of the mTNFH6NS3 Type 2b fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker.

Figure 7-2. Amino Acid sequence of the mTNFH6NS3 Type 2b fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker.

Figure 8-1. DNA coding sequence of the mTNFH6NS3 Type 2c fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker.

Figure 8-2. Amino Acid sequence of the mTNFH6NS3 Type 2c fusionprotein. Sequence depicted in bold is non-NS3 sequence. This sequence encodes the mTNF fusionpartner, the hexahistidine tag and part of the multilinker

EXAMPLES

Example 1. Expression of HCV NS3 Type 1b clone 19b in *E. coli*

1.1 Cloning of the HCV NS3 Type 1b clones 19a and 19b genes

The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from HCV subtype 1b serum IG8309 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers HCP_r59 (5'-GGGCCCCACCATGGGGGTTGCGAAGGCGGTGGACTT-3') (SEQ ID NO 1) and HCP_r60 (5'-CTATTAGCTGAAAGTCGACTGTCTGGGTGACAGCA-3') (SEQ ID NO 2). This yielded a PCR fragment 19 which was cloned into *E. coli*. The sense primer HCP_r59 introduces an *Apa*I restriction site which includes an artificial methionine. Antisense oligonucleotide HCP_r60 introduces a stopcodon after aa 1465. The PCR fragment was subsequently cut with *Apa*I and the resulting 833 bp *Apa*I fragment was cloned in the *Apa*I-cut expressionvector pmTNFHRP (Innogenetics, Ghent, Belgium). Four hepatitis C clones (HCC1) were sequenced. HCC119a and HCC119b (see deduced amino acid sequence given in Figure 1 and Figure 2-2). Clone HCC119b (pmTNFHRPHCC119b) was retained for further subcloning.

1.2 Construction of the expression plasmid pEmTNFMPHHCC119b

Starting from vector pmTNFHRPHCC119b the NS3 clone 19b coding sequence was isolated as a 900 bp *Nco*I fragment and inserted into the *Nco*I-cut expressionvector pEmTNFMPH (Innogenetics, Ghent, Belgium) resulting in vector pEmTNFMPHHCC119b. This plasmid expresses HCV NS3 clone 19b as an N-terminal fusionprotein with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs 19 and 20, Figure 2).

1.3 Expression of HCV NS3 clone 19b in *E. coli*

E. coli strain MC1061(pAcI) cells (Wertman et al., 1986) were transformed with plasmid pEmTNFMPHHCC119b. MC1061(pAcI) cells harboring pEmTNFMPHHCC119b were grown overnight in Luria Broth (LB) supplemented with 10 µg/ml tetracycline at 28°C. Cultures were

diluted 20 times in fresh LB, then grown at 28°C to an OD₆₀₀ of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 clone 19b fusion protein was analysed by western blotting using specific monoclonal antibodies and HCV positive human sera.

Example 2. Expression of HCV NS3 clone B9 in *E. coli*

2.1 Cloning of the HCV NS3 Type 1a clone B9 gene

The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from HCV subtype 1a serum IG21054 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers HCP_r59 (5'-GGGCCCCACCATGGGGGTTGCGAAGGCGGTGGACTT-3') (SEQ ID NO 1) and HCP_r60 (5'-CTATTAGCTGAAAGTCGACTGTCTGGGTGACAGCA-3') (SEQ ID NO 2). This yielded a PCR fragment B which was cloned into *E. coli*. The sense primer HCP_r59 introduces an *Apa*I restriction site which includes an artificial methionine. Antisense oligonucleotide HCP_r60 introduces a stopcodon after aa 1465. The PCR fragment was subsequently cloned in the pGEM-T vector (Promega, Madison, WI, US). Four clones were sequenced: B7, B9, B12, and B14 (see deduced amino acid sequences in Figure 1 and Figure 3-2). Clone B9 (pGEMTNS3B9) was retained for further subcloning.

2.2 Construction of the expressionplasmid pIGFH111NS3B9

Starting from vector pGEMTNS3B9, the clone B9 coding sequence was isolated as a 850 bp *Nco*I/*Spe*I blunted fragment and inserted into the *Nco*I/*Stu*I cut expression vector pIGFH111 (Innogenetics, Ghent, Belgium) resulting in vector pIGFH111NS3B9. This plasmid expresses HCV NS3 clone B9 as an N-terminal fusion protein with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs. 21 and 22, Figure 3).

2.3 Expression of HCV NS3 clone B9 in *E. coli*

E. coli strain MC1061(pAcI) (Wertman et al., 1986) cells were transformed with plasmid pIGFH111NS3B9. MC1061(pAcI) cells harboring pIGFH111NS3B9 were grown overnight in Luria Broth (LB) supplemented with 10 µg/ml tetracycline at 28°C. Cultures were diluted 20 times in fresh LB, then grown at 28°C to an OD₆₀₀ of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 clone B9 fusion protein was analysed on Western blot using specific monoclonal antibodies and HCV positive human sera.

Example 3. Expression of HCV NS3 Type 1a clones A26, C16, and D18 in *E. coli*

Clones A26, C16, and D18 were isolated from HCV subtype 1a infected sera IG21051, IG17790, and IG21068, respectively, in a similar way as described for clone B9 using primers HCP_r59 and HCP_r60. Initially, clones, A5, A26, C1, C3, C4, C12, C16, D17, D18, and D19, were cloned and sequenced (see deduced amino acid sequences given in Figure 1). Clones A26, C16, and D18 were retained for further subcloning.

Example 4. Expression of HCV NS3 Type 3a clones 21 and 32 in *E. coli*

4.1 Cloning of the HCV NS3 Type 3a clones 21 and 32 genes

The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from HCV subtype 3a sera IG21349 and IG20014 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers 403 (5'-GGGCCCCACCATAGGTGTAGCAAAAGCCCTACAGTT-3') (SEQ ID NO 33) and 404 (5'-CTATTAGCTGAAGTCAACGTACTGTTCAACAGC-3') (SEQ ID NO 34). This yielded in both cases a PCR fragment of approx. 850 bp which was subsequently subcloned in the pGEM-T vector (Promega, Madison, WI, US). From each cloned PCR fragment several clones were sequenced but from each serum only one cloned fragment proved to be completely correct upon sequencing. This was clone 21 (pGEM-TNS3T3a 21) for serum

IG21349 and clone 32 (pGEM-TNS3T3a 32) for serum IG20014 (Figures 4 and 5).

4.2 Construction of the expression plasmids pIGFH111NS3T3a.21 and pIGFH111NS3T3a.32

Starting from vectors pGEM-TNS3T3a.21 and pGEM-TNS3T3a 32, the clone 21 and 32 coding sequences were isolated as 850 bp NcoI/SalI fragments and inserted into the NcoI/SalI cut expression vector pIGFH111 (Innogenetics, Ghent, Belgium) resulting in vectors pIGFH111NS3T3a.21 and pIGFH111NS3T3a.32, respectively. These plasmids express HCV NS3 Type 3a clones 21 and 32 as N-terminal fusion proteins with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs 23-26, Figures 4 and 5)

4.3 Expression of HCV NS-3 Type 3a clones 21 and 32 in *E. coli*

E. coli strain MC1061(pAcI) (Wertman et al., 1986) cells were transformed with plasmids pIGFH111NS3T3a.21 and pIGFH111NS3T3a.32, respectively. MC1061(pAcI) cells harboring pIGFH111NS3T3a.21 or pIGFH111NS3T3a.32 were grown overnight in Luria Broth (LB) supplemented with 10 µg/ml tetracycline at 28°C. Cultures were diluted 20 times in fresh LB, then grown at 28°C to an OD600 of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 Type 3a clones 21 and 32 fusion proteins was analysed on Western blot using specific monoclonal antibodies and HCV positive human sera

Example 5. Expression of HCV NS3 Type 2a clone 3 in *E. coli*

5.1 Cloning of the HCV NS3 Type 2a clone 3 gene

The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from a HCV subtype 2a serum IG21342 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers 412 (5'-GGGCCCCACCATGGGCGTGGCCAAGTCCATAGACTT-3') (SEQ ID NO

35) and 413 (5'-CTATTAGCTGAAGTCTACAACCTTGAGTGACCGC-3') (SEQ ID NO 36) This yields a PCR fragment of approx 850 bp which was subsequently subcloned in the pGEM-T vector (Promega, Madison, WI, US) Several clones were sequenced and clone 3 (pGEM-TNS3T2a) was retained for further subcloning (Figure 6)

5.2 Construction of expression plasmid pIGFH111NS3T2a

5 Starting from vector pGEM-TNS3T2a, the clone 3 coding sequence was isolated as a 850 bp NcoI fragment and inserted into the NcoI cut expression vector pIGFH111 (Innogenetics, Ghent, Belgium) resulting in vector pIGFH111NS3T2a. This plasmid expresses HCV NS3 Type 2a clone 3 as an N-terminal fusion protein with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs 27 and 28, Figure 6)

5.3 Expression of HCV NS-3 Type 2a clone 3 in *E. coli*

15 *E. coli* strain MC1061(pAcI) (Wertman et al., 1986) cells were transformed with plasmid pIGFH111NS3T2a. MC1061(pAcI) cells harbouring pIGFH111NS3T2a were grown overnight in Luria Broth (LB) supplemented with 10 µg/ml tetracycline at 28°C. Cultures were diluted 20 times in fresh LB, then grown at 28°C to an OD600 of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 Type 2a clone 3 fusionprotein was analysed on Western blot using specific monoclonal antibodies and HCV positive human sera

Example 6. Expression of HCV NS3 Type 2b clone 9 in *E. coli*

20 6.1 Cloning of the HCV NS3 Type 2b clone 9 gene

The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from a HCV subtype 2b serum IG20192 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers 401 (5'-GGGCCCCACCATGGGCGTAGCCAAATCCATTGACTT-3') (SEQ ID NO

37) and 402 (5'-CTATTAGCTGAAGTCTACAATTTGAGAGACCGC-3') (SEQ ID NO 38) This yields a PCR fragment of approx 850 bp which was subsequently subcloned in the pGEM-T vector (Promega, Madison, WI, US) Several clones were sequenced and clone 9 was retained for further subcloning (Figure 7)

6.2 Construction of expression plasmid pIGFH111NS3T2b

Starting from vector pGEM-TNS3T2b, the clone 9 coding sequence was isolated as a 850 bp NcoI fragment and inserted into the NcoI cut expression vector pIGFH111 (Innogenetics, Ghent, Belgium) resulting in vector pIGFH111NS3T2b This plasmid expresses HCV NS3 Type 2b clone 9 as an N-terminal fusion protein with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs 29-30; Figure 7)

6.3 Expression of HCV NS-3 Type 2b clone 9 in *E. coli*

E. coli strain MC1061(pAcI) cells (Wertman et al., 1986) were transformed with plasmid pIGFH111NS3T2b MC1061(pAcI) cells harbouring pIGFH111NS3T2b were grown overnight in Luria Broth (LB) supplemented with 10 µg/ml tetracycline at 28°C. Cultures were diluted 20 times in fresh LB, then grown at 28°C to an OD600 of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 Type 2b clone 9 fusionprotein was analysed on Western blot using specific monoclonal antibodies and HCV positive human sera.

Example 7. Expression of HCV NS3 Type 2c clone 14 in *E. coli*

7.1 Cloning of the HCV NS3 Type 2c clone 14 gene

The NS3 helicase domain (amino acids 1188-1465) was amplified by RT-PCR from a HCV subtype 2c serum IG20031 (Innogenetics, Ghent, Belgium) using synthetic oligonucleotide primers 401 (5'-GGGCCCCACCATGGGCGTAGCCAAATCCATTGACTT-3') (SEQ ID NO 37) and 402 (5'-CTATTAGCTGAAGTCTACAATTTGAGAGACCGC-3') (SEQ ID NO 38)

This yields a PCR fragment of approx. 850 bp which was subsequently subcloned in the pGEM-T vector (Promega, Madison, WI, US). Several clones were sequenced and clone 14 (pGEM-TNS3T2c) was retained for further subcloning (Figure 8)

7.2 Construction of expression plasmid pIGFH111NS3T2c

Starting from vector pGEM-TNS3T2c, the clone 14 coding sequence was isolated as a 850 bp NcoI fragment and inserted into the NcoI cut expression vector pIGFH111 (Innogenetics, Ghent, Belgium) resulting in vector pIGFH111NS3T2c. This plasmid expresses HCV NS3 Type 2c clone 14 as an N-terminal fusion protein with the N-terminal 25 aa of murine TNF followed by a hexahistidine purification tag and a formic acid cleavage site (SEQ ID NOs 31 and 32; Figure 8)

7.3 Expression of HCV NS-3 Type 2c clone 14 in *E. coli*

E. coli strain MC1061(pAcI) cells (Wertman et al., 1986) were transformed with plasmid pIGFH111NS3T2c. MC1061(pAcI) cells harbouring pIGFH111NS3T2c were grown overnight in Luria Broth (LB) supplemented with 10 µg/ml tetracycline at 28°C. Cultures were diluted 20 times in fresh LB, then grown at 28°C to an OD₆₀₀ of 0.2, after which the temperature was raised to 42°C. At 2 to 3 hours post-induction, the cells were harvested. Expression of the HCV NS3 Type 2c clone 14 fusion protein was analysed on Western blot using specific monoclonal antibodies and HCV positive human sera.

Example 8. Purification of the NS3 helicase protein domain

Nine volumes of 8M Guanidinium hydrochloride (Gu HCl) and 1 volume of 0.2 M NaHPO₄ were added to each gram equivalent of wet *E. coli* cell paste and the solution was homogenized by continuously vortexing. Solid Na₂S₄O₆ and Na₂SO₃ were added to the solution up to a final concentration of 65 and 360 mM, respectively. CuSO₄ (stock solution: 0.1 M in 25% NH₃) was added up to a final concentration of 100 µM. The solution was stirred overnight in the dark at room temperature and after incubation at -70°C cleared by centrifugation at 4°C (30 min,

20 000 rpm, JA20 rotor)

Empigen BB™ (Aibright & Wilson Ltd, Okibury, UK) and imidazole were added to the supernatant up to a final concentration of 1% (w/v) and 20 mM, respectively. The pH was adjusted to 7.2 with 1N HCl. A sample corresponding to 3 L cell culture equivalent was loaded at 2 mL/min on a 25 mL Ni-IDA Sepharose FF (XK 16/20 column, Pharmacia, Upsala, Sweden), which had been equilibrated with buffer A containing 20 mM imidazole (buffer A: 50 mM phosphate, 6M Gu HCl, 1% Empigen, pH 7.2). The Ni-IDA Sepharose column was washed consecutively with

- buffer A containing 20mM imidazole
- buffer A containing 35 mM imidazole
- buffer A containing 50 mM imidazole
- buffer B containing 50 mM imidazole (buffer B: 50 mM phosphate, 6M Gu HCl, pH 7.2)
- buffer B containing 200 mM imidazole.

Each washing step was maintained during the chromatography until the absorbance at 280 nm reached baseline level. The column was regenerated with 50 mM EDTA, 500 mM NaCl, pH 7.0.

Fractions were analysed by SDS-PAGE using non-reducing conditions and silver staining. The mTNF-NS3 B9 fusion protein was recovered in the 200 mM imidazole elution. Western blotting using rabbit anti-human TNF (1 µg NS3/lane) and rabbit anti-*E. coli* (10 µg NS3/lane) showed that the NS3 exhibited a purity of over 99 % after this single chromatography step.

The 200 mM imidazole elution fractions were pooled and desalted.

A 40 mL Ni-IDA eluate sample was loaded at 10 mL/min on a 300 mL Sephadex G25 column (XK 50, Pharmacia, Upsala, Sweden) which had been equilibrated with 50 mM phosphate, 6M ureum, 1mM EDTA, pH 7.2. 10 mL-fractions were collected and the protein concentration was determined by the micro BCA method (Pierce, Rockford, IL, US). The protein concentration was adjusted to 500 µg/mL with the desalting buffer before desulphonation and reduction. The overall yield was 50-55 mg purified NS3 fusion protein/L culture equivalent.

Finally, DTT (stock solution: 100 mM in distilled water) was added in a 100-fold molar excess versus the cysteine content in the NS3 antigen (e.g. NS3 19b contains 7 cysteines). The solution was flushed with nitrogen and incubated for 1h at 28°C. The NS3 sample was subsequently diluted in the appropriate buffer for ELISA and LIA coating.

Example 9. NS3 helicase antibody reactivity tested in LIA

In order to test the NS3 helicase antibody reactivity, a line of 50 µg/ml NS3 antigen solution in phosphate buffered saline was applied onto nylon membrane strips. The strips were dried for at least 1 hour at a temperature between 18-24°C and were subsequently blocked with PBS/caseine in the presence (10 mM) or absence of the reducing agent DTT. The strips were subsequently washed with PBS containing Tween 20 and either no DTT or 10 mM DTT and with water containing either no DTT or 10 mM DTT and 1 mM EDTA. The membranes were dried for 30 minutes and cut into strips for testing of different patient samples.

The results of an experiment wherein strips were incubated with the anti-HCV seroconversion panel PHV903 (Boston Biomedica Inc., Boston, US) are given in Table 1

Example 10. NS3 helicase antibody reactivity tested in ELISA

In order to test the NS3 helicase antibody reactivity, ELISA plates were coated with the NS3 antigens purified as in Example 4 in the following way.

Microtiter plate wells were coated with NS3 protein at a concentration of 0.3 µg/ml NS3 protein in coating buffer containing 50 mM carbonate buffer, either 200 mM DTT or no DTT, and 1 mM EDTA. The microtiter plates are incubated for 18 hours at 20° C, and blocked with 300 µl of PBS/caseine buffer per well. The plates were incubated for 2 hours at 20°C and subsequently fixed with 300 µl of fixation buffer containing either 200 mM DTT or no DTT, and 1 mM EDTA for 2 hours at 20°C.

The results are shown in Tables 2 and 3. Table 2 gives the Signal to Noise values of assays including NS3 coated and fixed with or without DTT, with the BBI seroconversion panels PHV901 to PHV912. Table 3 shows a summary of the number of days in which HCV antibodies can be detected earlier by the assay incorporating DTT. Clearly, a total number of 34 days of earlier detection in 12 HCV seroconversions can be obtained by incorporating DTT in the assay.

Table 1. BBI panels tested in LLA coated with HCV NS3 as described in example 9.

PHV	+DTT ¹	-DTT ¹
903-01	-	-
903-02	-	-
903-03	+/-	-
903-04	2	-
903-05	2	+/-
903-06	2	+/-
903-07	4	2
903-08	4	2

¹-. no reaction; +positive reaction; intensity ratings are given in comparison with different cut off lines sprayed onto the same strip

Table 2: BBI panels tested in ELISA coated with HCV NS3 as described in example 10.

MEMBER ID#	BLEED DATE	+ DTT (OD ₄₅₀)	- DTT (OD ₄₅₀)
PHV901-01	09/23/93	0.1	0.3
PHV901-02	11/27/93	0.1	0.3
PHV901-03	12/29/93	2.0	2.9
PHV901-04	12/31/93	2.1	3.0
PHV901-05	01/05/94	2.2	3.1
PHV901-06	01/07/94	2.4	3.2
PHV901-07	02/01/94	4.1	6.0
PHV901-08	02/09/94	3.9	5.9
PHV901-09	03/01/94	4.0	7.9
PHV901-10	03/08/94	4.1	7.8
PHV901-11	04/14/94	4.2	8.3
PHV903-01	02/07/92	0.2	0.2
PHV903-02	02/12/92	0.9	0.9
PHV903-03	02/14/92	1.3	1.6
PHV903-04	02/19/92	2.5	2.7
PHV903-05	02/21/92	2.8	2.8
PHV903-06	02/26/92	3.2	4.6
PHV903-07	02/28/92	3.5	5.4
PHV903-08	03/04/92	3.5	4.1
PHV904-01	04/18/95	0.1	0.2
PHV904-02	04/20/95	0.1	0.3
PHV904-03	04/25/95	0.1	0.2
PHV904-04	04/27/95	0.1	0.2
PHV904-05	05/02/95	0.4	0.4
PHV904-06	05/09/95	0.8	0.5
PHV904-07	05/11/95	0.8	0.5
PHV905-01	11/17/95	0.1	0.2
PHV905-02	11/21/95	0.1	0.3
PHV905-03	11/24/95	0.1	0.3
PHV905-04	11/28/95	0.2	0.3
PHV905-05	12/01/95	0.5	0.3
PHV905-06	12/05/95	1.0	0.4
PHV905-07	12/08/95	2.5	0.8
PHV905-08	12/12/95	3.5	2.2
PHV905-09	12/15/95	3.5	3.2

MEMBER ID#	BLEED DATE	+ DTT	- DTT
PHV 907-01	04/06/96	0 1	0 2
PHV907-02	04/10/96	0 1	0 2
PHV907-03	04/13/96	0 1	0 2
PHV907-04	04/19/96	3 0	2 2
PHV907-05	04/24/96	3 7	4 1
PHV907-06	04/27/96	3 6	4 1
PHV907-07	09/17/96	3 9	7 6
PHV908-01	01/26/96	0 1	0 1
PHV908-02	01/29/96	0 1	0 1
PHV908-03	01/31/96	0 1	0 1
PHV908-04	02/06/96	0 1	0 1
PHV908-05	02/08/96	0 1	0 1
PHV908-06	02/14/96	0 2	0 1
PHV908-07	02/20/96	1 4	0 2
PHV908-08	02/22/96	1 6	0 2
PHV908-09	02/27/96	1 9	0 2
PHV908-10	03/01/96	2 3	0 2
PHV908-11	03/07/96	2 3	0 4
PHV908-12	03/11/96	2 8	0 5
PHV908-13	03/14/96	2 8	0 5
PHV909-01	01/28/96	0 1	0 4
PHV909-02	02/15/96	2 3	5 4
PHV909-03	02/17/96	2 4	5 3
PHV910-01	08/26/96	0 1	0 2
PHV910-02	08/30/96	0 4	0 2
PHV910-03	09/03/96	2 7	5 1
PHV910-04	09/06/96	3 6	6 4
PHV910-05	09/10/96	3 9	8 1
PHV911-01	10/30/96	0 1	0 2
PHV911-02	11/02/96	0 1	0 2
PHV911-03	11/13/96	2 1	4 0
PHV911-04	11/20/96	3 6	7 8
PHV911-05	11/23/96	3 7	7 7
PHV912-01	01/06/96	0 2	0 3
PHV912-02	01/10/96	0 2	0 2
PHV912-03	01/13/96	4 5	9 9

002707-49698960

MEMBER ID#	BLEED DATE	+DTT	-DTT
PHV902-01	02/10/92	0.1	0.2
PHV902-02	02/12/92	0.1	0.2
PHV902-03	02/17/92	0.1	0.3
PHV902-04	02/19/92	0.3	0.6
PHV902-05	02/24/92	2.6	3.9
PHV902-06	02/26/92	3.1	5.9
PHV902-07	03/02/92	3.4	6.5
PHV906-01	10/07/95	0.5	0.3
PHV906-02	10/09/95	0.5	0.4
PHV906-03	10/14/95	1.6	0.6
PHV906-04	10/17/95	1.5	1.2
PHV906-05	10/21/95	2.2	3.0
PHV906-06	10/24/95	2.5	4.5
PHV906-07	10/28/95	2.9	5.7

002101-49692960

Table 3. Overview of the BBI panels - numbers of days with earlier detection

PHV	+DTT	-DTT
901	0	0
902	0	0
903	0	0
904	0	0
905	7	0
906	3	0
907	0	0
908	24	0
910	0	0
911	0	0
912	0	0

REFERENCES

- Burns, J., Butler, J., Moran, J., and Whitesides, G. (1991) Selective reduction of disulfides by tris(2-carboxyethyl)phosphine. *J. Org. Chem.* 56, 2648-2650
- Chan, W. (1968) A method for the complete S sulfonation of cysteine residues in proteins. *Biochemistry* 7, 4247-4254
- 5 Claeys, H., Volckaerts, A., Verhaert, H., De Beenhouwer, H., and Vermynen, C (1992) Evaluation of anti-HCV capsid indeterminate samples *The Lancet* 340, 249
- Cole, R. (1967) Sulfitolysis. *Meth. Enzymol.* 11, 206.
- Coligan, J., Kruisbeek, A., Margulis, D., Shevach, E. and Strober, W. (1992) *Current protocols in immunology*. Wiley Interscience.
- 10 De Beenhouwer, H., Verhaert, H., Claeys, H., and Vermynen, C. (1992) Confirmation of hepatitis C virus positive blood donors by immunoblotting and polymerase chain reaction. *Vox Sang* 63, 198-203.
- Di Bisceglie, AM, Carithers, RL Jr, Gores, GJ (1998) Hepatocellular carcinoma. *Hepatology*. 28, 1161-1165.
- 15 Gallit, J. (1993) Restoring free sulfhydryl groups in synthetic peptides *Anal. Biochem.*, 214, 334-335.
- Holmgren, A. (1979) Thioredoxin catalyzes the reduction of insulin disulfides by

dithiothreitol and dihydrolipoamide. J Biol. Chem 254, 9627-9632.

Inglis, A., and Liu, T. (1970) The stability of cysteine and cystine during acid hydrolysis of proteins and peptides. J Biol Chem 245, 112-116

McFarlane, I., Smith, H., Johnson, P, Bray, G, Vergani, D, and Williams, R. (1990)
Hepatitis C virus antibodies in chronic active hepatitis. pathogenic factor or false-positive
5 result? The Lancet 335, 754-757

Maertens, G and Stuyver, L. (1997) Genotypes and Genetic variation of hepatitis C virus. In
Molecular Medicine of Hepatitis (Eds Zuckerman, A. and Harrison, T), Molecular Medical
Science Series (Eds. James, K. and Morris A) John Wiley and Sons Ltd., Chichester, England,
Chapter 13, pp 183-233.

10 Marin, M., Bresciani, S., Puoti, M., Rodella, A., Gussago, A., Ravaggi, A, Pizzocolo, G.,
Albertini, A., and Cariani, E (1994) Clinical significance of serum HCV RNA as marker of
HCV infection. J. Clin Microbiol. 32, 3008-3012.

Peeters, D., Dekeyser, F., DeLeys, R., Maertens, G., and Pollet, D. (1993) Confirmation of
anti-hepatitis C virus antibodies using the INNO-LIA HCV Ab III including Core, E2/NS1,
15 NS3, NS4, and NS5 epitopes International Symposium on Viral Hepatitis and Liver Disease,
Tokyo, abstract 413

Pollet, D, Saman, E, Peeters, D, Warmenbol, H., Heyndricks, L, Wouters, C, Beelaert, G,
van der Groen, G., and Van Heuverswyn, H. (1990) Confirmation and differentiation of
antibodies to human immunodeficiency virus 1 and 2 with a strip-based assay including
20 recombinant antigens and synthetic peptides Clin. Chem 37, 1700-1707.

Saito, I., Miyamura, T., Ohbayashi, A., Harada, H., Katayama, T., Kikuchi, S., Watanabe, Y., Koi, S., Onji, M., Ohta, Y., Choo, Q.-L., Houghton, M., and Kuo, G. (1990) Proc. Natl Acad. Sci. USA 87, 6547-6549

Singh, R., and Kats, L. (1995) Catalysis of reduction of disulfide by selenol. Anal. Biochem. 232, 86-91.

5 Stuyver, L., Fretz, C., Esquivel, C., Boudifa, A., Jaulmes, D., Azar, N., Lunel, F., Leroux-Roels, G., Maertens, G., and Fournel, J. (1996) HCV genotype analysis in apparently healthy anti-HCV positive Parisian blood donors. Transfusion 36, 552-558

Thakur, M., DeFulvio, J., Richard, M., and Park, C. (1991) Technetium-99m labeled monoclonal antibodies: evaluation of reducing agents. Nucl. Med. Biol., 18, 227- 233.

10 Waumans, L., Claeys, H., Verhaert, H., Mertens, W., and Vermeylen, C. (1993) Hepatitis C virus confirmation in blood donor screening. Vox. Sang. 64, 145-149

Wertman K.F., Wyman A.R. and Botstein D. (1986) Host/vector interactions which affect the viability of recombinant phage lambda clones. Gene 49: 253-262

15 Zaaijer, H., Vrielink, H., van Exel-Oehlers, P., Cuypers, H., and Lelie, P. (1994) Confirmation of hepatitis C infection. a comparison of five immunoblot assays. Transfusion 34, 603-607

CLAIMS

1. Solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent

2 Method for producing or carrying out an immunoassay according to claim 1, wherein said reducing agent is added to said solid phase during the steps of coating, blocking and/or fixation of said antigen to said solid phase or during pretreatment of the solid phase

3. Method according to claim 2 wherein said reducing agent is added to said solid phase during the step of coating the antigen to the solid phase

4. Method according to claim 2, wherein said reducing agent is added to said solid phase during the step of blocking said solid phase comprising the antigen applied thereto in the presence or absence of a reducing agent.

5. Method according to claim 2, wherein said reducing agent is added to said solid phase during the step of fixation of said solid phase comprising the antigen applied thereto in the presence or absence of a reducing agent

6. Method according to claim 2, wherein said reducing agent is added during pretreatment of the solid phase comprising the antigen applied thereto in the presence or absence of a reducing agent.

7 Method according to any of claims 1 to 6 wherein said reducing agent is DTT, DTE or TCEP

8 Method according to any of claims 1 to 7 wherein said reducing agent is used in a concentration range of 0.1 mM to 1 M, more particularly from 0.5 mM to 500 mM, even more particular from 1 mM to 250 mM, some applications may require ranges from 0.5 to 50 mM, 1 to 30 mM, 2 to 20 mM, or 5 to 15 mM, or about 10 mM.

9. Method according to any of claims 2 to 8 wherein said antigen is an HCV NS3 protein

5 10 Solid phase immunoassay produced by a method according to any of claims 2 to 9

11. ELISA produced by a method according to any of claims 2 to 9

12. ELISA according to claim 11 wherein said reducing agent is added in the coating and/or fixation steps.

13. QUICK test produced by a method according to any of claims 2 to 9

10 14. QUICK test according to claim 13 wherein said reducing agent is added in the blocking step.

15. Line Immunoassay produced by a method according to any of claims 2 to 9.

16. Line Immunoassay according to claim 15 wherein said reducing agent is added in the blocking step.

15 17. Use of an assay according to claims 10 to 16 for in vitro diagnosis of antibodies raised against an antigen as described in claim 1.

18 HCV NS3 protein treated by a method comprising the steps of sulphonation and subsequent desulphonation

19 HCV NS3 protein according to claim 18 which is additionally treated with a zwitter-ionic detergent, preferably Empigen

20 Method for purifying a cysteine containing recombinantly expressed protein comprising at least 2, preferably 3 or 4 and even more preferably all of the following steps

(a) sulphonation of a lysate from recombinant host cells or lysis of recombinant host cells in the presence of guanidinium chloride followed by a subsequent sulphonation of the cell lysate,

(b) treatment with a zwitterionic detergent, preferably after removal of the cell debris,

(c) purification of the sulphonated version of the recombinant protein or purification of the sulphonated version of the recombinant protein with subsequent removal of the zwitterionic detergent, with said purification being preferably chromatography, more preferably a Ni-IMAC chromatography with said recombinant protein being a His-tagged recombinant protein,

(d) desulphonation of the sulphonated version of the recombinant protein, preferably with a molar excess of DTT,

(e) storage in the presence of a molar excess of DTT, or immediate use in an assay.

21 An HCV polynucleic acid encoding a polypeptide as depicted in Figure 1 (SEQ ID NOs 3-18) or a unique part of an HCV polynucleic acid, more particularly a polynucleic acid having a sequence as represented in Figures 2-1, 3-1, 4-1, 5-1, 6-1, 7-1 or 8-1 (SEQ ID NOs 19, 21, 23, 25, 27, 29 and 31)

22 An HCV polynucleic acid according to claim 21 as depicted in Figures 2-1, 3-1, 4-1, 5-1, 6-1, 7-1 or 8-1 and characterized by the fact that its product does not react with falsly positive

HCV samples, or a part thereof which encodes a NS3 epitope which does not react with falsely positive HCV samples.

23 A recombinant vector comprising a polynucleic acid according to claim 21 or 22.

24 A host cell comprising a vector according to claim 23

25 A method for detecting a nucleic acid sequence according to claim 21 or 22 comprising.

5 -contacting said nucleic acid with a probe

-determining the complex formed between said nucleic acid and said probe

26. An isolated nucleic acid according to claim 21 or 22 or a fragment thereof for use as a probe or a primer for the detection of a nucleic acid according to claim 21 or 22.

27. A diagnostic kit for the detection of a nucleic acid sequence according to claim 21 or 22, comprising at least one primer and/or at least one probe according to claim 26.

28. An HCV polypeptide having part or all of the amino acid sequences of a polypeptide encoded by a polynucleic acid according to claim 21 or 22.

29. An HCV NS3 helicase protein or part thereof containing either S1200, A1218, A1384, P1407, V1412, P1424, or F1444, or a combination of these amino acids with any of the following amino acids L1201, S1222, I1274, S1289, T1321, A1323, T1369, L1382, V1408, A1409, F1410.

30. A pharmaceutical composition comprising a polypeptide according to claim 28 or 29, or

any functionally equivalent variant or fragment thereof.

31 A pharmaceutical composition comprising a polypeptide according to claim 28 or 29, or any functionally equivalent variant or fragment thereof for use as a medicament to prevent or treat HCV infection

32. A method for detecting a polypeptide according to claim 28 or 29 comprising,

-contacting said polypeptide with a ligand binding to said polypeptide

-determining the complex formed between said polypeptide and said ligand.

33 A ligand binding to a polypeptide according to claim 28 or 29

34. A composition comprising at least a ligand according to claim 33, in a pharmaceutical acceptable excipient, for use as a medicament.

35 A method for the production of a polypeptide according to claim 28 or 29 for diagnostic or therapeutic purposes.

002101"49698960

Figure 1 - 1

NS3A5	MGVAKAVDFIPVENLETTMRSPVFTDNSSPPAVPQSFQVAHLHAPTGSGKSTKVPAAYAA
NS3A26	-----T-----V-----
NS3B7	-----S-----G-----
NS3B9	-----S-----
NS3B12	-----S-----
NS3B14	-----S-----
NS3C1	-----SM-----T-----
NS3C3	-----SM-----T-----S-----
NS3C4	-----SM-----T-----
NS3C12	-----SM-----T-----
NS3C16	-----SM-----T-----
NS3D17	-----
NS3D18	-----D-----
NS3D19	-----
NS3HCCL19A	-----V-----SM-----T-----
NS3HCCL19B	-----V-----SM-----T-----

2/19

Figure 1 - 2

NS3A5	QGFKVLVLNPSVAATLGFAYMSRAHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCS
NS3A26	-----
NS3B7	--Y-----L-----KV-----
NS3B9	--Y-----K-----
NS3B12	--Y-----K-----
NS3B14	--Y-M-----K-Y-----T-----R
NS3C1	--Y-----K-----G-----A-----
NS3C3	--Y-----K-----G-----A-----
NS3C4	--Y-----K-----G-----A-----
NS3C12	--Y-----K-----G-----A-----
NS3C16	--Y-----K-----G-----A-----
NS3D17	--Y-----K-----V-----
NS3D18	--Y-----K-----V-----N-----
NS3D19	--Y-----K-----V-----
NS3HCCL19A	--Y-----K-----V-----A-----
NS3HCCL19B	--Y-----K-----V-----A-----

3/19

GGAYD
MICDE
CHST
DATS
ILGIG
TVLID
QAE
TAGAR
LVVL
ATA
APPG
SVTV
P
HP
NTE
EE
VA

Figure 1 - 3

NS3A5	GGAYD	MICDE	CHST	DATS	ILGIG	TVLID	QAE	TAGAR	LVVL	ATA	APPG	SVTV	P	HP	NTE	EE	VA
NS3A26	---	I---	---	---	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3B7	---	I---	---	---	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3B9	---	I---	---	---	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3B12	---	I---	---	---	---	D---	---	---	---	---	---	---	T---	---	---	---	---
NS3B14	---	I---	---	---	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3C1	---	I---	---	S-T	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3C3	---	I---	---	S-T	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3C4	---	I---	---	S-T	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3C12	---	I---	---	S-T	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3C16	---	I---	---	S-T	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3D17	---	I---	---	V---	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3D18	---	I---	---	V---	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3D19	---	I---	---	V---	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3HCCL19A	---	I---	---	I-S	---	---	---	---	---	---	---	---	T---	---	---	---	---
NS3HCCL19B	---	I---	---	I-S	---	---	---	---	---	---	---	---	T---	---	---	---	---

11

NS3A5	LSTTGEIPFYGKAIPLEAIKGRHLIFCHSKKKCDELAAKLTALGVNAVAYYRGLDVSVI
NS3A26	-----R-----
NS3B7	-----C-----
NS3B9	-----N-V-----P-----
NS3B12	-----P-V-----P-----
NS3B14	-----V-----V-----
NS3C1	-----N-----T-----V-----
NS3C3	-----N-----T-----SS-L-----
NS3C4	-----N-----T-----SS-L-----
NS3C12	-----N-----T-----SS-L-----
NS3C16	-----N-----T-----SS-L-----
NS3D17	-----SS-L-----
NS3D18	-----K-----V-----I-----
NS3D19	-----V-----I-----
NS3HCCL19A	-----SI-----I-V-----QV-----I-----
NS3HCCL19B	-----S-----I-V-----SGV-----I-----
	-----SGF-----I-----

Figure 1 - 5

NS3A5	PTSGDVVVVATDALMTGYTGDFDSVIDCNTCVTQTVDIFS	(SEQ ID NO 3)
NS3A26	-----	(SEQ ID NO 4)
NS3B7	-----	(SEQ ID NO 5)
NS3B9	-----F-----	(SEQ ID NO 6)
NS3B12	-----F-----	(SEQ ID NO 7)
NS3B14	-----F-----R	(SEQ ID NO 8)
NS3C1	-----F-----A-----	(SEQ ID NO 9)
NS3C3	-----F-----A-----	(SEQ ID NO 10)
NS3C4	-----F-----	(SEQ ID NO 11)
NS3C12	-----F-----	(SEQ ID NO 12)
NS3C16	-----F-----	(SEQ ID NO 13)
NS3D17	-----I-----	(SEQ ID NO 14)
NS3D18	-----	(SEQ ID NO 15)
NS3D19	-----	(SEQ ID NO 16)
NS3HCCL19A	-----F-----	(SEQ ID NO 17)
NS3HCCL19B	-----F-----	(SEQ ID NO 18)

6/19

Figure 2-1

ATGGTAAGATCAAGTAGTCAAAATTTCGAGTGACAAGCCTGTAGCCCACGTCGTAGCAAAC
CACCAAGTGGAGGAGCAGGGAATTCACCATCACCATCACCACGTGGATCCCGGGCCCATG
GGGGTTGCGAAGGCGGTGGACTTTGTACCCGTAGAGTCTATGGAAACCACCATGCGGTCC
CCGGTCTTTACGGATAACTCATCTCCTCCGGCCGTACCGCAGACATTCCAAGTGGCCCAT
CTACACGCCCCCACTGGTAGTGGCAAGAGCACTAAGGTGCCGGCTGCATATGCAGCCCAA
GGGTACAAGGTACTTGTCTTGAACCCATCCGTTGCCGCCACCTTAGGATTCGGGGCGTAT
ATGTCTAAAGCACATGGTGTTCGACCCTAACATTAGAACTGGGGTAAGGACCATCACCACG
GGCGCCCCCATTACGTACTCCACCTACGGCAAGTTTCTTGCCGACGGTGGTTGCTCTGGG
GGCGCTTACGACATCATAATATGTGATGAGTGCCACTCGATTGACTCAACCTCCATCTTG
GGCATCGGCACCGTCCTGGATCAGGCGGAGACGGCTGGAGCGCGGCTTGTCTGCTCGCC
ACTGCTACACCTCCGGGGTCGGTCACCGTGCCACATCCCAACATCGAGGAGGTGGCTCTG
TCCAGCACTGGAGAGATCCCCTTTTATGGCAAAGCCATCCCCATCGAGGTCATCAAAGGG
GGGAGGCACCTCATTTTCTGCCATTCCAAGAAGAAATGTGACGAGCTCGCCGCAAAGCTA
TCGGGCTTCGGAATCAACGCTGTAGCGTATTACCGAGGCCTTGATGTGTCCGTATACCG
ACTAGCGGAGACGTCGTTGTTGTGGCAACAGACGCTCTAATGACGGGCTTTACCGGCGAC
TTTGACTCAGTGATCGACTGTAACACATGCGTCACCCAGACAGTCGACTTCAGCTAA

(SEQ ID NO 19)

DQ22707.1-1969960

7/19

Figure 2-2

MVRSSSQNSSDKPVAHVVANHQVEEQGIHHHHHHVDPGPMGVAKAVDFVPVESMETTMRSPVFTD
NSSPPAVPQTFQVAHLHAPTGS GKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGVDPN
IRTGVRTITTGAPITYSTY GKFLADGGC SGGAYDIIICDECHSIDSTSILGIGTVLDAQETAGAR
LVVLATATPPGSVTVPHPNIEEVALSSTGEIPFYGKAIPIEVIKGRHLIFCHSKKKCDELA AKL
SGFGINAVAYYRGLDVSVIPTSGDVVVVATDALMTGFTGDFDSVIDCNTCVTQTVD FS

(SEQ ID NO 20)

002101-4953960

8/19

Figure 3-1

ATGGTAAGATCAAGTAGTCAAAATTTCGAGTGACAAGCCTGTAGCCACGTCGTAGCAAACCACCA
AGTGGAGGAGCAGGGAATTCACCATCACCATCACCACGTGGATCCCGGGCCCATGGGGGTTGCGA
AGGCGGTGGACTTTATCCCCGTGGAGAGCCTAGAAACAACCATGAGGTCCCCGGTGTTCACAGAC
AACTCCTCCCCGCCAGCAGTGCCCCAGAGCTTCCAGGTGGCCCCACCTGCATGCTCCACCGGCAG
CGGTAAGAGCACCAAGGTCCCGGCCGCATATGCGGCTCAGGGCTACAAAGTGCTGGTGCTCAACC
CCTCCGTTGCTGCAACATTGGGCTTTGGTGCTTACATGTCCAAGGCCCATGGGATTGATCCTAAC
ATCAGGACTGGGGTAAGGACAATTACTACTGGCAGCCCCATCACGTACTCCACCTACGGCAAGTT
CCTTGCCGACGGCGGGTGCTCGGGGGGTGCTTATGACATAATAATTTGTGACGAGTGCCACTCCA
CAGATGCAACATCTATTTTGGGCATCGGCACTGTCTTGACCAAGCAGAGACTGCGGGGGCGAGA
CTGGTTGTGCTTGCCACCGCTACCCCTCCGGGCTCCGTCACTGTGCCCCATCCTAATATCGAGGA
GGTTGCTCTGTCCACCACCGGAGAGATCCCTTTTACGGCAAGGCTATCCCCCTTGAGGCAATCA
AAGGGGGGAGACATCTCATCTTCTGCCACTCAAAGAAGAAGTGCGACGAACTCGCCGCCAAACCG
GTCGCGTTGGGTGTCAATGCCGTGGCTTACTACCGCGGCCTTGACGTGCCCGTCATCCCGACCAG
TGGCGATGTTGTGTCGTGGCAACTGATGCTCTCATGACCGGTTTTACCGGTGACTTCGACTCGG
TGATAGACTGTAATACGTGTGTCACCCAGACAGTCGACTTCAGCTAA

(SEQ ID NO 21)

002107-4969950

9/19

Figure 3-2

MVRSSSQNSSDKPVAHVVANHQVEEQGIHHHHHHVDPGPMGVAKAVDFIPVESLETTMRSPVFTD
NSSPPAVPQSFQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPN
IRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGAR
LVVLATATPPGSVTVPHPNIEEVALSTTGEIPFYGKAIPLEAIKGRHLIFCHSKKKCDELAAP
VALGVNAVAYYRGLDVPVIPTSGDVVVVATDALMTGFTGDFDSVIDCNTCVTQTVDFS

(SEQ ID NO 22)

002101 49692550

10/19

Figure 4-1

ATGGTAAGATCAAGTAGTCAAAATTGAGTGACAAGCCTGTAGCCCACGTCTGTAGCAAAC
CACCAAGTGGAGGAGCAGGGAATTCACCATCACCATCACCACGTGGATCCCGGGCCCATG
GCCGCGGGATTGGGCCCCCCCCATAGGTGTAGCAAAAGCCCTACAGTTCATACCAGTGGAA
ACCCTTAGTACGCAGGCTAGGTCTCCATCTTTCTCTGACAATTCAACTCCTCCTGCTGTC
CCACAGAGCTATCAAGTAGGGTATCTTCATGCCCCGACCGGCAGCGGTAAGAGCACAAAG
GTCCCGGCCGCTTATGTAGCACAAAGGATATAATGTTCTCGTGCTGAATCCATCGGTGGCG
GCCACACTAGGCTTCGGCTCTTTCATGTGCGGTGCCTATGGGATCGACCCCAACATCCGC
ACTGGGAACCGCACCGTCACTAACTGGTGCTAACTGACCTATTCCACCTACGGTAAGTTT
CTCGCGGACGGGGGTTGCTCCGGGGGGGCATATGATGTAATTATCTGTGATGAATGTTCAT
GCCCCAAGACGCCACTAGCATATTGGGCATAGGCACGGTCTTAGATCAGGCCGAGACGGCT
GGGGTGAGGCTGACGGTTTTAGCGACAGCAACTCCCCCAGGCAGCATCACTGTGCCACAT
TCTAACATCGAGGAAGTGGCCCTGGGCTCTGAAGGTGAGATCCCTTTCTACGGTAAGGCT
ATACCGATAGCCCTGCTCAAGGGGGGGAGACACCTCGTCTTTTGCCATTCCAAGAAAAA
TGTGATGAGCTAGCATCCAACTCAGAGGTATGGGGCTCAACGCTGTGGCGTACTATAGG
GGTCTCGATGTTTCCGTCATACCAACAACAGGAGACGTCGTGGTCTGCGCTACTGACGCC
CTCATGACTGGATTCACTGGAGACTTCGATTCTGTCTAGACTGCAACGTGGCTGTTGAA
CAGTACGTTGACTTCAGCTAA

(SEQ ID NO 23)

002101"49698960

11/19

Figure 4-2

MVRSSSQNSSDKPVAHVVANHQVEEQGIHHHHHHVDPGPMAAGLGPPIGVAKALQFIPVE
TLSTQARSPSFSDNSTPPAVPQSYQVGYLHAPTGSGKSTKVPAAAYVAQGYNVLVLNPSVA
ATLGFGSEMSRAYGIDPNIRTNRTVTTGAKLTYSTYGKFLADGGCSGGAYDVIICDECH
AQDATSILGIGTVLDQAETAGVRLTVLATATPPGSITVPHSNIEEVALGSEGEIPFYGKA
IPIALLKGGRHLVTFCHSKKKCDELASKLRGMGLNAVAYYRGLDVSVIPTTGDVVVCATDA
LMTGFTGDFDSVIDCNVAVEQYVDFS

(SEQ ID NO 24)

002101"49698960

12/19

Figure 5-1

ATGGTAAGATCAAGTAGTCAAAATTCGAGTGACAAGCCTGTAGCCACGTCGTAGCAAAC
CACCAAGTGGAGGAGCAGGGAATTCACCATCACCATCACCACGTGGATCCCGGGCCCATG
GCCGCGGGATTGGGCCCCACCATAGGTGTAGCAAAAGCCCTACAGTTCATACCAGTGGAA
ACCCCTTAGCACACAGGCTAGGTCTCCATCTTTCTCTGACAATTCAACTCCTCCTGCTGTT
CCACAGAGCTATCAAGTAGGGTACCTTCATGCCCCGACCGGCAGCGGTAAGAGCACAAAG
GTCCCGGGCCGCTTATGTAGCACAAAGGATATACTGTTCTCGTGCTGAATCCATCGGTGGCG
GCCACACTAGGCTTCGGCTCTTTTCATGTCGCGTGCCTATGGGATCGACCCCAACATCCGC
ACTGGGAACCGCACCGTTACAACCTGGTGCTAAACTGACCTATTCCACCTACGGTAAGTTT
CTTGCGGATGGGGGTTGCTCCGGGGGGGCATATGATGTGATTATCTGTGATGAGTGTCAT
GCCCAAGACGCTACTAGCATATTGGGTATAGGCACGGTCTTAGATCAGGCCGAGACGGCT
GGGGTGAGGCTGACGGTTTTAGCGACAGCGACCCCCCAGGCAGCATCACTGTGCCACAT
TCTAACATCGAAGAAGTGGCCCTGGGCTCTGAGGGTGAGATCCCCTTCTACGGCAAGGCT
ATACCGATATCCCTGCTCAAGGGGGGGAGGCACCTTATCTTTTGCCATTCCAAAAAAAAG
TGTGATAAGATAGCGTCCAAACTCAGAGGCATGGGGCTCAACGCTGTAGCGTACTATAGA
GGTCTCGATGTGTCCGTCATACCAACAACAGGAGACGTCGTAGTTTGGCGCTACTGACGCC
CTCATGACTGGATACACCGGGGACTTCGATTCTGTCATAGACTGCAACGTGGCTGTTGAA
CAGTACGTTGACTTCAGCTAA

(SEQ ID NO 25)

=

DDEPOT 4969950

14/19

Figure 6-1

ATGGTAAGATCAAGTAGTCAAAATTTCGAGTGACAAGCCTGTAGCCCACGTCGTAGCAAAC
CACCAAGTGGAGGAGCAGGGAATTCACCATCACCATCACCACGTGGATCCCGGGCCCATG
GGCGTGGCCAAGTCCATAGACTTCATCCCCGTTGAGACACTCGACATCGTTACGCGGTCC
CCCACCTTTAGTGACAACAGCACGCCACCGGCTGTGCCCCAGACCTATCAGGTCGGGTAC
TTGCATGCCCCAACCGGCAGCGGAAGAGCACCAAAGTCCCCGTCGCATACGCCGCCAG
GGGTATAAAGTGTTAGTGCTCAATCCCTCGGTGGCTGCTACCCTGGGGTTTGGAGCGTAC
CTGTCCAAGGCACACGGCATCAATCCCAACATTAGGACTGGAGTCAGGACTGTGACGACT
GGCGAAGCCATCACGTACTCCACGTATGGCAAATTCCTCGCCGATGGGGGCTGCGCAGGT
GGCGCCTATGACATCATCATATGCGATGAATGCCACGCCGTGGATGCCACTACCATTCCTC
GGCATCGGAACAGTCCTTGACCAAGCAGAGACAGCCGGGGTCAGGCTAACTGTGCTGGCT
ACGGCCACGCCCCCGGGTCAGTGACAACCCCCCATCCCAACATAGAGGAGGTAGCCCTC
GGGCAGGAGGGTGAGACCCCCCTTCTATGGGAGGGCGATCCCCCTGTCTTACATCAAGGGA
GGGAGACACTTGATCTTCTGCCACTCAAAGAAAAAGTGTGACGAGCTCGCGGCGGCCCTC
CGGGGCATGGGCCTGAACGCTGTGGCGTACTACAGAGGGCTCGACGTCTCCGTAATACCA
GCTCAGGGAGATGTAGTGGTCGTCGCCACCGACGCCCTCATGACGGGGTTCAGTGGAGAC
TTTGACTCCGTGATCGACTGCAATGTAGCGGTCACTCAAGTTGTAGACTTCAGCTAA

(SEQ ID NO 27)

002701 49598960

15/19

Figure 6-2

MVRSSSQNSSDKPVAHVVANHQVEEQGIHHHHHHVDPGPMGVAKSIDFIPVETLIDIVTRS
PTFSDNSTPPAVPQTYQVGYLHAPTGS GKSTKVPVAYAAQGYKVLVNLNPSVAATLGFGAY
LSKAHGINPNIRTGVRTVTTGEAITYSTYGKFLADGGCAGGAYDIIICDECHAVDATTIL
GIGTVLDQAETAGVRLTVLATATPPGSVTTPHPNIEEVALGQEGETPFYGRAIPLSYIKG
GRHLIFCHSKKKCDELAAALRGMGLNAVAYYRGLDVSVIPAQGDVVVVATDALMTGFTGD
FDSVIDCNVAVTQVVDFS

(SEQ ID NO 28)

002701-49698960

16/19

Figure 7-1

ATGGTAAGATCAAGTAGTCAAAATTGAGTGACAAGCCTGTAGCCACGTCGTAGCAAAC
CACCAAGTGGAGGAGCAGGGAATTCACCATCACCATCACCACGTGGATCCCGGGCCCATG
GGCGTAGCCAAATCCATTGACTTCATCCCTGTTGAATCTCTCGATATCGCCTCACGGTCA
CCCAGTTTCTCTGACAACAGCAGCCACCAGCTGTGCCTCAGTCCTACCAGGTGGGCTAT
TTGCACGCGCCAACGGGCAGCGGGAAGAGCACCAAGGTCCCTGTGCGATATGCTAGTCAG
GGGTATAAAGTACTCGTGCTAAATCCCTCTGTGCGGGCCACGCTCGGCTTCGGGGCCTAC
ATGTCCAAAGCCCACGGGATCAACCCCAACATCAGAACCAGGGGTACGGACTGTGACCACC
GGGGACCCCATCACCTACTCCACTTATGGCAAGTTTCTCGCAGATGGGGGCTGCTCAGCC
GGCGCCTATGATGTCATCATATGCGATGAATGCCACTCAGTGGACGCTACTACCATCCTT
GGCATTGGAACAGTCCTCGACCAGGCCGAGACCGCGGGTGCTAGGTTAGTGGTTTTAGCC
ACAGCCACGCCTCCTGGTACAGTGACAACCTCCTCATAGCAACATAGAGGAGGTGGCTCTT
GGTCATGAAGGCGAGATCCCTTTCTACGGCAAGGCTATTCCCCTAGCTTTCATCAAGGGG
GGCAGACACCTAATCTTTTGCCATTCAAAGAAGAAGTGCGATGAGCTCGCGGCAGCCCTT
CGGGGCATGGGTGTCAACGCCGTTGCTTACTATAGGGGTCTCGACGTCTCTGTTATACCA
ACTCAAGGAGACGTGGTGGTCGTTGCCACCGATGCCCTAATGACTGGATACACCGGTGAC
TTTGA CTCTGTTATTGACTGCAACGTTGCGGTCTCTCAAATTGTAGACTTCAGCTAA

(SEQ ID NO 29)

17/19

Figure 7-2

MVRSSSQNSSDKPVAHVVANHQVEEQGIHHHHHHVDPGPMGVAKSIDFIPVESLDIASRS
PSFSDNSTPPAVPQSYQVGYLHAPTGS GKSTKVPVAYASQGYKVLVLNPSVAATLGFGAY
MSKAHGINPNIRTGVRTVTTGDPITYSTYGKFLADGGCSAGAYDVIIICDECHSV DATTIL
GIGTVLDQAETAGARLVVLATATPPGTVTTPHSNIEEVALGHEGEIPFYGKAIPLAFIKG
GRHLIFCHSKKKCDELAAALRGMGVNAVAYYRGLDVSVIPTQGDV VVVATDALMTGYTGD
FDSVIDCNVAVSQIVDFS

(SEQ ID NO 30)

0962994.000

18/19

Figure 8-1

ATGGTAAGATCAAGTAGTCAAAATTTCGAGTGACAAGCCTGTAGCCCACGTCGTAGCAAAC
CACCAAGTGGAGGAGCAGGGAATTCACCATCACCATCACCACGTGGATCCCGGGCCCATG
GGCGTAGCCAAATCCATTGACTTCATCCCCGTTGAGTCTCTCGACATCGTGACTAGGTCT
CCAAGCTTCACTGACAACAGTACACCTCCAGCCGTGCCTCAGACCTACCAAGTGGGGTAT
CTCCACGCGCCCCACTGGTAGCGGGAAGAGTACCAAGGTCCCTGCAGCGTACGCCGCTCAG
GGGTACAAGGTGCTGGTACTGAACCCCTCCGTGGCTGCCACTTTGGGATTTGGGGCCTAC
ATGTCAAAGCGCACGGAGTCAATCCCAATATCAGGACCGGGGTTTCGCACGGTGAACACT
GGGGATCCCATCACCTACTCCACGTATGGCAAATTCCTCGCAGATGGAGGCTGCTCTGGA
GGCGCCTATGGCATCATAATATGCGACGAATGCCATTTCGACGGAATCCACGACCATCCTC
GGCATCGGGACCGTTCTCGACCAAGCTGAGACAGCTGGAGTTAGGTTGGTGGTCTTGGCC
ACGGCGACCCACCCGGATCTGTAACAACCCACACCCCAACATAGAGGAGGTGGCCCTC
GGCCACGAGGGCGAAATCCCCTTCTATGGGAAGGCCATCCCTCTCTCAACCATCAAGGGA
GGACGACATCTAATCTTCTGTCATTCAAAGAAAAGTGCGACGAGCTCGCGGTGGCCCTC
CGAGCGATGGGCCTTAACGCGGTGGCATACTACAGAGGGCTTGACGTCTCCGTGATACCA
ACACAAGGAGACGTGGTGGTCTCGCCACCGACGCCCTCATGACAGGATATACTGGAGAC
TTCGACTCTGTGATCGACTGCAACATGGCGGTCTCTCAAATTGTAGACTTCAGCTAA

(SEQ ID NO 31)

10021001 13692950

19/19

Figure 8-2

MVRSSSQNSSDKPVAHVVANHQVEEQGIHHHHHHVDPGPMGVAKSIDFIPVESLDIVTRS
PSFTDNSTPPAVPQTYQVGYLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAY
MSKAHGVNPNIRTGVRTVNTGDPITYSTYGKFLADGGCSGGAYGIIICDECHSTDSTIIL
GIGTVLDQAETAGVRLVVLATATPPGSVTTPHPNIEEVALGHEGEIPFYGKAIPLSTIKG
GRHLIFCHSKKKCDELAVALRAMGLNAVAYYRGLDVSVIPTQGDVVVVATDALMTGYTGD
FDSVIDCNMAVSQIVDFS

(SEQ ID NO 32)

002207 43693960

RULE 53 (37 C.F.R. 1.63)
INVENTORS DECLARATION FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

IMPROVED IMMUNODIAGNOSTIC ASSAYS USING REDUCING AGENTS

the specification of which (check applicable box(es)):

☐ is attached hereto
☒ was filed on _____ as U.S. Application Serial No. _____ (Att'y Dkt. No. 2581-48)
☒ was filed as PCT International application No. PCT/EP99/02547 on APRIL 15, 1999
and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/385 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number
98870087.5Country
EPDay/Month/Year Filed
17 April 1998

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

Application Number


Date/Month/Year Filed


I hereby claim the benefit under 35 U.S.C. 120/385 of all prior United States and PCT International applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT International filing date of this application:

Prior U.S./PCT Application(s):

Application Serial No.
PCT/EP99/02547Day/Month/Year Filed
APRIL 15, 1999Status: patented
pending, abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 5th Floor, Arlington, VA 22201-4714, telephone number (703) 818-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 28327; Larry S. Nixon, 28840; Robert A. Vanderhye, 27078; James T. Hoamer, 30184; Robert W. Fark, 31352; Richard G. Beate, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32108; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Michard, 29009; Duane M. Byers, 33383; Jeffrey H. Nelson, 30481; John R. Lastova, 33148; H. Warren Buman, Jr. 29368; Thomas E. Byrne, 32208; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36683; James D. Berquist, 34778; Updeep S. Gill, 37334; Michael J. Shea, 34728; Donald L. Jackson, 41090; Michelle N. Leater, 32331; Frank P. Presta, 19828; Joseph B. Presta, 35329; Joseph A. Rhoads, 37515; Raymond Y. Mah, 41428. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1. Inventor's Signature:  Date: 27/09/00
Inventor: Geert (first) MAERTENS (last) Belgium (citizenship)
Residence: (city) BRUGGE (state/country) BELGIUM
Post Office Address: Zilverpansstraat 84, BRUGGE, BELGIUM
(Zip Code) B-8310

2. Inventor's Signature:  Date: 27/9/00
Inventor: Joost (first) LOUWAGIE (last) Belgium (citizenship)
Residence: (city) ZWIJNDRECHT (state/country) BELGIUM
Post Office Address: Meisjesstraat 45, ZWIJNDRECHT, BELGIUM
(Zip Code) B-2070

FOR ADDITIONAL INVENTORS, check box ☒ and attach sheet with same information and signature and date for each.

458547

3. Inventor's Signature: [Signature] Date: September 22, 2000
Inventor: Aifone BOSMAN Belgium
(first) (last) (citizenship)
Residence: (city) OPWIJK MI (state/country) BELGIUM
Post Office Address: Hulst 188, OPWIJK, BELGIUM
(Zip Code) B-1748
4. Inventor's Signature: [Signature] Date: September 20, 2000
Inventor: Ertin SABLON Belgium
(first) (last) (citizenship)
Residence: (city) MERCHTEM MI (state/country) BELGIUM
Post Office Address: Robbroeklaan 1A, MERCHTEM, BELGIUM
(Zip Code) B-1788
5. Inventor's Signature: [Signature] Date: September 19, 2000
Inventor: Maen ZREIN France
(first) (last) (citizenship)
Residence: (city) BONDUES MI (state/country) FRANCE
Post Office Address: 201, domaine de la Vigne, BONDUES, FRANCE
(Zip Code) F-59810

FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information and signature and date for each.

09586964-101200

458847

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAERTENS et al

Atty. Ref.: 2551-48

Serial No. To Be Assigned

Group:

Filed: October 12, 2000

Examiner:

For: IMPROVED IMMUNODIAGNOSTIC
ASSAYS USING REDUCING AGENTS

* * * * *

October 12, 2000

Assistant Commissioner for Patents
Washington, DC 20231

Sir:


LETTER

The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B.J. Sadoff

Reg. No. 36,663

BJS:pd
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

[illegible]

Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser
35 40 45

[illegible][illegible]

Thr Gln Thr Val Asp Phe Ser
275

<210> 7

<211> 279

<212> PRT

<213> Hepatitis C virus

<400> 7

Met Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Leu Glu
1 5 10 15

Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala
20 25 30

Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser
35 40 45

Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys
50 55 60

Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala
65 70 75 80

Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val
85 90 95

Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys
100 105 110

Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile
115 120 125

Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Asp Ile Gly
130 135 140

Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu
145 150 155 160

Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile
165 170 175

Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys
180 185 190

Ala Ile Pro Leu Glu Ala Ile Lys Gly Gly Arg His Leu Ile Phe Cys
195 200 205

His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu
210 215 220

Gly Val Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile
225 230 235 240

0956064.10300

220

```
<210> 9
<211> 279
<212> PRT
<213> Hepatitis C virus
```

<400>	9															
Met	Gly	Val	Ala	Lys	Ala	Val	Asp	Phe	Ile	Pro	Val	Glu	Ser	Met	Glu	
1				5					10					15		
Thr	Thr	Met	Arg	Ser	Pro	Val	Phe	Thr	Asp	Asn	Ser	Ser	Pro	Pro	Ala	
			20					25					30			
Val	Pro	Gln	Thr	Phe	Gln	Val	Ala	His	Leu	His	Ala	Pro	Thr	Gly	Ser	
		35					40					45				
Gly	Lys	Ser	Thr	Lys	Val	Pro	Ala	Ala	Tyr	Ala	Ala	Gln	Gly	Tyr	Lys	
	50					55					60					
Val	Leu	Val	Leu	Asn	Pro	Ser	Val	Ala	Ala	Thr	Leu	Gly	Phe	Gly	Ala	
65					70					75					80	
Tyr	Met	Ser	Lys	Ala	His	Gly	Ile	Asp	Pro	Gly	Ile	Arg	Thr	Gly	Val	
				85					90					95		
Arg	Thr	Ile	Thr	Thr	Gly	Ala	Pro	Ile	Thr	Tyr	Ser	Thr	Tyr	Gly	Lys	
			100					105					110			
Phe	Leu	Ala	Asp	Gly	Gly	Cys	Ser	Gly	Gly	Ala	Tyr	Asp	Ile	Ile	Ile	
		115					120					125				
Cys	Asp	Glu	Cys	His	Ser	Thr	Asp	Ser	Thr	Thr	Ile	Leu	Gly	Ile	Gly	
	130					135					140					
Thr	Val	Leu	Asp	Gln	Ala	Glu	Thr	Ala	Gly	Ala	Arg	Leu	Val	Val	Leu	
145					150					155					160	
Ala	Thr	Ala	Thr	Pro	Pro	Gly	Ser	Val	Thr	Val	Pro	His	Pro	Asn	Ile	
				165					170					175		
Glu	Glu	Val	Ala	Leu	Ser	Asn	Thr	Gly	Glu	Ile	Pro	Phe	Tyr	Gly	Lys	
			180					185					190			

Ala Ile Pro Leu Glu Thr Ile Lys Gly Gly Arg His Leu Ile Phe Cys
195 200 205

His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Ser Leu
210 215 220

Gly Leu Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile
225 230 235 240

Pro Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr
245 250 255

Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Ala
260 265 270

Thr Gln Thr Val Asp Phe Ser
275

<210> 10
<211> 279
<212> PRT
<213> Hepatitis C virus

<400> 10
Met Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Met Glu
1 5 10 15

Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala
20 25 30

Val Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser
35 40 45

Ser Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys
50 55 60

Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala
65 70 75 80

Tyr Met Ser Lys Ala His Gly Ile Asp Pro Gly Ile Arg Thr Gly Val
85 90 95

Arg Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys
100 105 110

Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile
115 120 125

Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly
130 135 140

Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu
145 150 155 160

002201-1060000

Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile
165 170 175

Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys
180 185 190

Ala Ile Pro Leu Glu Thr Ile Lys Gly Gly Arg His Leu Ile Phe Cys
195 200 205

His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Ser Leu
210 215 220

Gly Leu Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile
225 230 235 240

Pro Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr
245 250 255

Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Ala
260 265 270

Thr Gln Thr Val Asp Phe Ser
275

<210> 11

<211> 279

<212> PRT

<213> Hepatitis C virus

<400> 11

Met Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Met Glu
1 5 10 15

Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala
20 25 30

Val Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser
35 40 45

Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys
50 55 60

Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala
65 70 75 80

Tyr Met Ser Lys Ala His Gly Ile Asp Pro Gly Ile Arg Thr Gly Val
85 90 95

Arg Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys
100 105 110

Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile
115 120 125

Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly

002201-10100

140

Arg Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys
100 105 110

[illegible]

00210T-4959950

Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile
115 120 125

Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly
130 135 140

Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu
145 150 155 160

Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile
165 170 175

Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys
180 185 190

Ala Ile Pro Leu Glu Thr Ile Lys Gly Gly Arg His Leu Ile Phe Cys
195 200 205

His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Ser Leu
210 215 220

Gly Leu Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile
225 230 235 240

Pro Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr
245 250 255

Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val
260 265 270

Thr Gln Thr Val Asp Phe Ser
275

<210> 13

<211> 279

<212> PRT

<213> Hepatitis C virus

<400> 13

Met Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Met Glu
1 5 10 15

Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala
20 25 30

Val Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser
35 40 45

Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys
50 55 60

Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala
65 70 75 80

60

Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala
20 25 30

Table 1. Demographic characteristics of the study population	
Age (years)	50.0 ± 10.0
Gender	
Male	50.0%
Female	50.0%
Education	
High school	50.0%
University	50.0%
Occupation	
White collar	50.0%
Blue collar	50.0%
Unemployed	50.0%
Marital status	
Married	50.0%
Single	50.0%
Divorced	50.0%
Widowed	50.0%
Smoking status	
Smoker	50.0%
Non-smoker	50.0%
Alcohol consumption	
Alcohol consumer	50.0%
Non-alcohol consumer	50.0%
Family size	3.0 ± 1.0
Household size	3.0 ± 1.0
Income (TL/month)	1000.0 ± 500.0
Health insurance	
Health insurance holder	50.0%
Non-health insurance holder	50.0%
Chronic diseases	
Hypertension	50.0%
Diabetes	50.0%
Coronary artery disease	50.0%
Chronic kidney disease	50.0%
Chronic liver disease	50.0%
Chronic lung disease	50.0%
Chronic mental disease	50.0%
Chronic infectious disease	50.0%
Chronic autoimmune disease	50.0%
Chronic cancer	50.0%
Chronic other diseases	50.0%
Current medications	
Antihypertensive	50.0%
Antidiabetic	50.0%
Cardiovascular	50.0%
Renal	50.0%
Hepatic	50.0%
Pulmonary	50.0%
Psychiatric	50.0%
Infectious	50.0%
Immunosuppressive	50.0%
Anticancer	50.0%
Other	50.0%
Comorbidities	
Hypertension and diabetes	50.0%
Hypertension and coronary artery disease	50.0%
Hypertension and chronic kidney disease	50.0%
Hypertension and chronic liver disease	50.0%
Hypertension and chronic lung disease	50.0%
Hypertension and chronic mental disease	50.0%
Hypertension and chronic infectious disease	50.0%
Hypertension and chronic autoimmune disease	50.0%
Hypertension and chronic cancer	50.0%
Hypertension and chronic other diseases	50.0%
Diabetes and coronary artery disease	50.0%
Diabetes and chronic kidney disease	50.0%
Diabetes and chronic liver disease	50.0%
Diabetes and chronic lung disease	50.0%
Diabetes and chronic mental disease	50.0%
Diabetes and chronic infectious disease	50.0%
Diabetes and chronic autoimmune disease	50.0%
Diabetes and chronic cancer	50.0%
Diabetes and chronic other diseases	50.0%
Coronary artery disease and chronic kidney disease	50.0%
Coronary artery disease and chronic liver disease	50.0%
Coronary artery disease and chronic lung disease	50.0%
Coronary artery disease and chronic mental disease	50.0%
Coronary artery disease and chronic infectious disease	50.0%
Coronary artery disease and chronic autoimmune disease	50.0%
Coronary artery disease and chronic cancer	50.0%
Coronary artery disease and chronic other diseases	50.0%
Chronic kidney disease and chronic liver disease	50.0%
Chronic kidney disease and chronic lung disease	50.0%
Chronic kidney disease and chronic mental disease	50.0%
Chronic kidney disease and chronic infectious disease	50.0%
Chronic kidney disease and chronic autoimmune disease	50.0%
Chronic kidney disease and chronic cancer	50.0%
Chronic kidney disease and chronic other diseases	50.0%
Chronic liver disease and chronic lung disease	50.0%
Chronic liver disease and chronic mental disease	50.0%
Chronic liver disease and chronic infectious disease	50.0%
Chronic liver disease and chronic autoimmune disease	50.0%
Chronic liver disease and chronic cancer	50.0%
Chronic liver disease and chronic other diseases	50.0%
Chronic lung disease and chronic mental disease	50.0%
Chronic lung disease and chronic infectious disease	50.0%
Chronic lung disease and chronic autoimmune disease	50.0%
Chronic lung disease and chronic cancer	50.0%
Chronic lung disease and chronic other diseases	50.0%
Chronic mental disease and chronic infectious disease	50.0%
Chronic mental disease and chronic autoimmune disease	50.0%
Chronic mental disease and chronic cancer	50.0%
Chronic mental disease and chronic other diseases	50.0%
Chronic infectious disease and chronic autoimmune disease	50.0%
Chronic infectious disease and chronic cancer	50.0%
Chronic infectious disease and chronic other diseases	50.0%
Chronic autoimmune disease and chronic cancer	50.0%
Chronic autoimmune disease and chronic other diseases	50.0%
Chronic cancer and chronic other diseases	50.0%

Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Asp Ser
35 40 45

Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys
50 55 60

Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala
65 70 75 80

Tyr Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Arg Thr Gly Val
85 90 95

Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys
100 105 110

Phe Leu Ala Asn Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile
115 120 125

Cys Asp Glu Cys His Ser Thr Asp Val Thr Ser Ile Leu Gly Ile Gly
130 135 140

Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu
145 150 155 160

Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile
165 170 175

Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys
180 185 190

Ala Ile Pro Leu Glu Ala Ile Lys Gly Gly Arg His Leu Ile Phe Cys
195 200 205

His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu
210 215 220

Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile
225 230 235 240

Pro Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr
245 250 255

Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val
260 265 270

Thr Gln Thr Val Asp Phe Ser
275

<210> 16

<211> 279

<212> PRT

<213> Hepatitis C virus

<400> 16

<211> 279

<212> PRT

<213> Hepatitis C virus

<400> 18

Met Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu
1 5 10 15

Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala
20 25 30

Val Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser
35 40 45

Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys
50 55 60

Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala
65 70 75 80

Tyr Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Arg Thr Gly Val
85 90 95

Arg Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys
100 105 110

Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile
115 120 125

Cys Asp Glu Cys His Ser Ile Asp Ser Thr Ser Ile Leu Gly Ile Gly
130 135 140

Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu
145 150 155 160

Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile
165 170 175

Glu Glu Val Ala Leu Ser Ser Thr Gly Glu Ile Pro Phe Tyr Gly Lys
180 185 190

Ala Ile Pro Ile Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys
195 200 205

His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Phe
210 215 220

Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile
225 230 235 240

Pro Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr
245 250 255

<210> 25
 <211> 981
 <212> DNA
 <213> Hepatitis C virus

<400> 25
 atggttaagat caagtagtca aaattcgagt gacaagcctg tagccacgt cgtagcaaac 60
 caccaagtgg aggagcaggg aattcaccat caccatcacc acgtggatcc cgggcccacg 120
 gccgcgggat tgggcccac cataggtgta gcaaaagccc tacagttcat accagtggaa 180
 acccttagca cacaggctag gtctccatct ttctctgaca attcaactcc tcctgctgtt 240
 ccacagagct atcaagtagg gtaccttcat gccccgaccg gcagcggtaa gagcaciaag 300
 gtcccggccg cttatgtagc acaaggatat actgttctcg tgctgaatcc atcgggtggcg 360
 gccacactag gcttcggctc tttcatgtcg cgtgcctatg ggatcgaccc caacatccgc 420
 actgggaacc gcaccgttac aactgggtgct aaactgacct attccaccta cggtaagttt 480
 cttgcggatg ggggttgctc cgggggggca tatgatgtga ttatctgtga tgagtgtcat 540
 gcccgaagacg ctactagcat attgggtata ggacaggtct tagatcaggc cgagacggct 600
 ggggtgaggg tgacggtttt agcgacagcg accccccag gcagcatcac tgtgccacat 660
 tctaacatcg aagaagtggc cctgggctct gaggggtgaga tcccccttcta cggcaaggct 720
 ataccgatat ccctgctcaa gggggggagg caccttatct ttgcccattc caaaaaaag 780
 tgtgataaga tagcgtccaa actcagaggc atggggctca acgctgtagc gtactataga 840
 ggtctcgatg tgtccgtcat accaacaaca ggagacgtcg tagtttgccg tactgacgcc 900
 ctcattgactg gatacaccgg ggacttcgat tctgtcatag actgcaacgt ggctgttgaa 960
 cagtacgttg acttcagcta a 981

<210> 26
 <211> 326
 <212> PRT
 <213> Hepatitis C virus

<400> 26
 Met Val Arg Ser Ser Ser Gln Asn Ser Ser Asp Lys Pro Val Ala His
 1 5 10 15
 Val Val Ala Asn His Gln Val Glu Glu Gln Gly Ile His His His His
 20 25 30
 His His Val Asp Pro Gly Pro Met Ala Ala Gly Leu Gly Pro Thr Ile
 35 40 45
 Gly Val Ala Lys Ala Leu Gln Phe Ile Pro Val Glu Thr Leu Ser Thr
 50 55 60
 Gln Ala Arg Ser Pro Ser Phe Ser Asp Asn Ser Thr Pro Pro Ala Val
 65 70 75 80
 Pro Gln Ser Tyr Gln Val Gly Tyr Leu His Ala Pro Thr Gly Ser Gly
 85 90 95
 Lys Ser Thr Lys Val Pro Ala Ala Tyr Val Ala Gln Gly Tyr Thr Val
 100 105 110
 Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ser Phe

115	120	125
Met Ser Arg Ala Tyr Gly Ile Asp Pro Asn Ile Arg Thr Gly Asn Arg		
130	135	140
Thr Val Thr Thr Gly Ala Lys Leu Thr Tyr Ser Thr Tyr Gly Lys Phe		
145	150	155
Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Val Ile Ile Cys		
165	170	175
Asp Glu Cys His Ala Gln Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr		
180	185	190
Val Leu Asp Gln Ala Glu Thr Ala Gly Val Arg Leu Thr Val Leu Ala		
195	200	205
Thr Ala Thr Pro Pro Gly Ser Ile Thr Val Pro His Ser Asn Ile Glu		
210	215	220
Glu Val Ala Leu Gly Ser Glu Gly Glu Ile Pro Phe Tyr Gly Lys Ala		
225	230	235
Ile Pro Ile Ser Leu Leu Lys Gly Gly Arg His Leu Ile Phe Cys His		
245	250	255
Ser Lys Lys Lys Cys Asp Lys Ile Ala Ser Lys Leu Arg Gly Met Gly		
260	265	270
Leu Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro		
275	280	285
Thr Thr Gly Asp Val Val Val Cys Ala Thr Asp Ala Leu Met Thr Gly		
290	295	300
Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Val Ala Val Glu		
305	310	315
Gln Tyr Val Asp Phe Ser		
325		

<210> 27
 <211> 957
 <212> DNA
 <213> Hepatitis C virus

<400> 27
 atggttaagat caagtagtca aaattcgagt gacaagcctg tagcccacgt cgtagcaaac 60
 caccaagtgg aggagcaggg aattcaccat caccatcacc acgtggatcc cgggcccattg 120
 ggcgtggcca agtccataga cttcatcccc gttgagacac tcgacatcgt tacgcgggtcc 180
 cccaccttta gtgacaacag cagccaccg gctgtgcccc agacctatca ggctcgggtac 240
 ttgcatgccc caaccggcag cggaaagagc accaaagtcc ccgtcgcata cgccgcccag 300
 ggggtataaag tgtagtgct caatccctcg gtggctgcta ccctgggggtt tggagcgtac 360
 ctgtccaagg cacacggcat caatcccaac attaggactg gagtcaggac tgtgacgact 420
 ggccaagcca tcacgtactc cacgtatggc aaattcctcg ccgatggggg ctgcgcaggt 480

```

ggcgcctatg acatcatcat atgcgatgaa tgccacgccg tggatgccac taccattctc 540
ggcatcggaa cagtccttga ccaagcagag acagccgggg tcaggctaac tgtgctggct 600
acggccacgc cccccgggtc agtgacaacc ccccatccca acatagagga ggtagccctc 660
gggcaggagg gtgagacccc cttctatggg agggcgatcc ccctgtctta catcaaggga 720
gggagacact tgatcttctg ccaactcaaag aaaaagtgtg acgagctcgc ggcgccctc 780
cggggcatgg gcctgaacgc tgtggcgtag tacagagggc tcgacgtctc cgtaatacca 840
gctcagggag atgtagtggt cgtcgccacc gacgccctca tgacggggtt cactggagac 900
tttgactccg tgatcgactg caatgtagcg gtcactcaag ttgtagactt cagctaa 957

```

<210> 28

<211> 318

<212> PRT

<213> Hepatitis C virus

<400> 28

```

Met Val Arg Ser Ser Ser Gln Asn Ser Ser Asp Lys Pro Val Ala His
  1             5             10             15

```

```

Val Val Ala Asn His Gln Val Glu Glu Gln Gly Ile His His His His
          20             25             30

```

```

His His Val Asp Pro Gly Pro Met Gly Val Ala Lys Ser Ile Asp Phe
          35             40             45

```

```

Ile Pro Val Glu Thr Leu Asp Ile Val Thr Arg Ser Pro Thr Phe Ser
          50             55             60

```

```

Asp Asn Ser Thr Pro Pro Ala Val Pro Gln Thr Tyr Gln Val Gly Tyr
          65             70             75             80

```

```

Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Val Ala
          85             90             95

```

```

Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala
          100            105            110

```

```

Ala Thr Leu Gly Phe Gly Ala Tyr Leu Ser Lys Ala His Gly Ile Asn
          115            120            125

```

```

Pro Asn Ile Arg Thr Gly Val Arg Thr Val Thr Thr Gly Glu Ala Ile
          130            135            140

```

```

Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ala Gly
          145            150            155            160

```

```

Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ala Val Asp Ala
          165            170            175

```

```

Thr Thr Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala
          180            185            190

```

```

Gly Val Arg Leu Thr Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val
          195            200            205

```

```

Thr Thr Pro His Pro Asn Ile Glu Glu Val Ala Leu Gly Gln Glu Gly
          210            215            220

```

002207-1369960

Glu Thr Pro Phe Tyr Gly Arg Ala Ile Pro Leu Ser Tyr Ile Lys Gly
 225 230 235 240
 Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu
 245 250 255
 Ala Ala Ala Leu Arg Gly Met Gly Leu Asn Ala Val Ala Tyr Tyr Arg
 260 265 270
 Gly Leu Asp Val Ser Val Ile Pro Ala Gln Gly Asp Val Val Val Val
 275 280 285
 Ala Thr Asp Ala Leu Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val
 290 295 300
 Ile Asp Cys Asn Val Ala Val Thr Gln Val Val Asp Phe Ser
 305 310 315

<210> 29
 <211> 957
 <212> DNA
 <213> Hepatitis C virus

<400> 29
 atggttaagat caagtagtca aaattcgagt gacaagcctg tagccacgt cgtagcaaac 60
 caccaagtgg aggagcagg aattcaccat caccatcacc acgtggatcc cgggcccattg 120
 ggcgtagcca aatccattga cttcatccct gttgaatctc tcgatatcgc ctcacgggtca 180
 cccagtttct ctgacaacag cacgccacca gctgtgcctc agtcctacca ggtggggctat 240
 ttgcacgcgc caacgggcag cggaagagc accaagggtcc ctgtcgcata tgctagtcag 300
 ggggtataaag tactcgtgct aaatccctct gtcgcggcca cgctcggctt cggggcctac 360
 atgtccaaag cccacgggat caacccaac atcagaaccg gggtagcgac tgtgaccacc 420
 ggggaccca tcacctact cacttatggc aagtttctcg cagatggggg ctgctcagcc 480
 ggcgcctatg atgtcatcat atgcgatgaa tgccactcag tggacgctac taccatcctt 540
 ggcattggaa cagtcctcga ccaggccgag accgcgggtg ctaggttagt ggttttagcc 600
 acagccacgc ctcttggtac agtgacaact cctcatagca acatagagga ggtggctctt 660
 ggtcatgaag gcgagatccc tttctacggc aaggctattc ccctagcttt catcaagggg 720
 ggcagacacc taatcttttg ccattcaaag aagaagtgcg atgagctcgc ggcagccctt 780
 cggggcatgg gtgtcaacgc cgttgcttac tataggggtc tcgacgtctc tgttatacca 840
 actcaaggag acgtgggtgg cgttgccacc gatgccctaa tgactggata caccgggtgac 900
 tttgactctg ttattgactg caacgttgcg gtctctcaaa ttgtagactt cagctaa 957

<210> 30
 <211> 318
 <212> PRT
 <213> Hepatitis C virus

<400> 30
 Met Val Arg Ser Ser Ser Gln Asn Ser Ser Asp Lys Pro Val Ala His
 1 5 10 15
 Val Val Ala Asn His Gln Val Glu Glu Gln Gly Ile His His His His
 20 25 30

002101-10100

His	His	Val	Asp	Pro	Gly	Pro	Met	Gly	Val	Ala	Lys	Ser	Ile	Asp	Phe	
		35					40					45				
Ile	Pro	Val	Glu	Ser	Leu	Asp	Ile	Ala	Ser	Arg	Ser	Pro	Ser	Phe	Ser	
	50					55					60					
Asp	Asn	Ser	Thr	Pro	Pro	Ala	Val	Pro	Gln	Ser	Tyr	Gln	Val	Gly	Tyr	
65					70					75					80	
Leu	His	Ala	Pro	Thr	Gly	Ser	Gly	Lys	Ser	Thr	Lys	Val	Pro	Val	Ala	
				85					90					95		
Tyr	Ala	Ser	Gln	Gly	Tyr	Lys	Val	Leu	Val	Leu	Asn	Pro	Ser	Val	Ala	
			100					105					110			
Ala	Thr	Leu	Gly	Phe	Gly	Ala	Tyr	Met	Ser	Lys	Ala	His	Gly	Ile	Asn	
		115					120						125			
Pro	Asn	Ile	Arg	Thr	Gly	Val	Arg	Thr	Val	Thr	Thr	Gly	Asp	Pro	Ile	
	130					135						140				
Thr	Tyr	Ser	Thr	Tyr	Gly	Lys	Phe	Leu	Ala	Asp	Gly	Gly	Cys	Ser	Ala	
145					150					155					160	
Gly	Ala	Tyr	Asp	Val	Ile	Ile	Cys	Asp	Glu	Cys	His	Ser	Val	Asp	Ala	
			165						170					175		
Thr	Thr	Ile	Leu	Gly	Ile	Gly	Thr	Val	Leu	Asp	Gln	Ala	Glu	Thr	Ala	
		180						185					190			
Gly	Ala	Arg	Leu	Val	Val	Leu	Ala	Thr	Ala	Thr	Pro	Pro	Gly	Thr	Val	
		195					200					205				
Thr	Thr	Pro	His	Ser	Asn	Ile	Glu	Glu	Val	Ala	Leu	Gly	His	Glu	Gly	
	210					215						220				
Glu	Ile	Pro	Phe	Tyr	Gly	Lys	Ala	Ile	Pro	Leu	Ala	Phe	Ile	Lys	Gly	
225					230					235					240	
Gly	Arg	His	Leu	Ile	Phe	Cys	His	Ser	Lys	Lys	Lys	Cys	Asp	Glu	Leu	
			245						250					255		
Ala	Ala	Ala	Leu	Arg	Gly	Met	Gly	Val	Asn	Ala	Val	Ala	Tyr	Tyr	Arg	
			260					265						270		
Gly	Leu	Asp	Val	Ser	Val	Ile	Pro	Thr	Gln	Gly	Asp	Val	Val	Val	Val	
	275						280					285				
Ala	Thr	Asp	Ala	Leu	Met	Thr	Gly	Tyr	Thr	Gly	Asp	Phe	Asp	Ser	Val	
	290					295					300					
Ile	Asp	Cys	Asn	Val	Ala	Val	Ser	Gln	Ile	Val	Asp	Phe	Ser			
305					310					315						

